Scolaris Content Display Scolaris Content Display

Parto temprano programado versus conducta expectante para mujeres con rotura prematura de membranas antes del trabajo de parto prematuro antes de las 37 semanas de gestación para mejorar el resultado del embarazo

Collapse all Expand all

References

References to studies included in this review

Cox 1995 {published data only}

Cox SM, Leveno KJ. Intentional delivery vs expectant management with preterm ruptured membranes at 30‐34 weeks' gestation. Obstetrics & Gynecology 1995;86:875‐9. CENTRAL
Cox SM, Leveno KJ, Sherman ML, Travis L, DePalma R. Ruptured membranes at 30 to 34 weeks: intentional delivery vs expectant management. American Journal of Obstetrics and Gynecology 1995;172:412. CENTRAL

Eroiz‐Hernandez 1997 {published data only}

Eroiz‐Hernandez J, Trejo‐Acuna MA, Alvarez‐Tarin MH. Conservative management of premature membrane rupture in pregnancy of 28‐34 weeks. Aleatory clinical trial [Manejo conservador de ruptura prematura de membranas en embarazos de 28 a 34 semanas. Essayo clinico aleatorio]. Ginecologia y Obstetricia de Mexico 1997;65:43‐7. CENTRAL

Garite 1981 {published data only}

Garite TJ, Freeman RK, Linzey EM, Braly PS, Dorchester WL. Prospective randomised study in corticosteroids in the management of premature rupture of the membranes and the premature gestation. American Journal of Obstetrics and Gynecology 1981;141(5):508‐15. CENTRAL

Iams 1985 {published data only}

Iams JD, Talbert ML, Barrows H, Sachs L. Management of preterm prematurely ruptured membranes: a prospective randomized comparison of observation vs use of steroids and timed delivery. American Journal of Obstetrics and Gynecology 1985;151:32‐8. CENTRAL

Koroveshi 2013 {published data only}

Koroveshi G, Qirko R, Koroveshi E, Kuli G, Kodra N, Nurce A, et al. Incidence of sepsis in late preterm babies born from pregnancies complicated with premature preterm rupture of membranes. Journal of Perinatal Medicine 2013;41(Suppl 1):Abstract no:622. CENTRAL

Mercer 1993 {published data only}

Mercer B, Crocker L, Boe N, Sibai B. Induction versus expectant management in PROM with mature amniotic fluid at 32‐36 weeks: a randomized trial. American Journal of Obstetrics and Gynecology 1993;168(1 Pt 2):295. CENTRAL
Mercer BM, Crocker LG, Boe NM, Sibai BM. Induction vs expectant management in premature rupture of the membranes with mature amniotic fluid at 32 to 36 weeks: a randomized trial. American Journal of Obstetrics and Gynecology 1993;169:775‐82. CENTRAL

Morris 2016 {published data only}

Morris J, Roberts CL, Bond DM, Crowther C. Immediate delivery versus expectant care in women with preterm prelabour rupture of the membranes close to term (PPROMT) ‐ a progress report. Journal of Paediatrics and Child Health 2012;48(Suppl 1):96. CENTRAL
Morris JA, Roberts CL, Patterson JA, Bond DM, Crowther CA, Bowen JR, et al. Immediate delivery versus expectant care in women with preterm prelabour rupture of the membranes close to term (PPROMPT): a multi‐centre randomised controlled trial. Archives of Disease in Childhood 2014;99(Suppl 2):A223. CENTRAL
Morris JM, Algert C, Crowther C, Bond D, Bowen J, Roberts CL. Preterm pre‐labour rupture of the membranes close to term (PPROMT) trial. Journal of Paediatrics and Child Health 2014;50(Suppl 1):23‐4. CENTRAL
Morris JM, Roberts CL, Bowen JR, Patterson JA, Bond DM, Algert CS, et al. Immediate delivery compared with expectant management after preterm pre‐labour rupture of the membranes close to term (PPROMT trial): a randomised controlled trial. Lancet 2016;387(10017):444‐52. CENTRAL
Morris JM, Roberts CL, Crowther CA, Buchanan SL, Henderson‐Smart DJ, Salkeld G. Protocol for the immediate delivery versus expectant care of women with preterm prelabour rupture of the membranes close to term (PPROMT) trial. BMC Pregnancy and Childbirth 2006;6:9. CENTRAL

Naef 1998 {published data only}

Naef RW, Allbert JR, Ross EL, Weber M, Martin RW, Morrison JC. Premature rupture of membranes at 34 to 37 weeks' gestation: aggressive versus conservative management. American Journal of Obstetrics and Gynecology 1998;178(1):126‐30. CENTRAL
Naef RW, Allbert JR, Ross EL, Weber M, Martin RW, Morrison JC. Premature rupture of the membranes at 34‐37 weeks' gestation: aggressive vs conservative management. American Journal of Obstetrics and Gynecology 1994;170:340. CENTRAL

Nelson 1985 {published data only}

Nelson LH, Meis PJ, Hatjis CG, Ernest JM, Dillard R, Schey HM. Premature rupture of membranes: a prospective, randomized evaluation of steroids, latent phase, and expectant management. Obstetrics & Gynecology1985; Vol. 66:55‐8. CENTRAL

Spinnato 1987 {published data only}

Spinnato JA, Shaver DC, Bray EM, Lipshitz J. Preterm premature rupture of the membranes with fetal pulmonary maturity present: a prospective study. Obstetrics & Gynecology1987; Vol. 69:196‐201. CENTRAL
Spinnato JA, Shaver DC, Bray EM, Lipshitz J. Preterm premature rupture of the membranes with fetal pulmonary maturity present: a prospective study. Proceedings of 6th Annual Meeting of the Society of Perinatal Obstetricians; 1986 Jan 30‐Feb 1; San Antonio, Texas, USA. 1986:82. CENTRAL

Van der Ham 2012a {published data only}

Mol BW, Vijgen S, Opmeer B, Bijlenga D, Akerboom B, Van Wijngaarden W, et al. Economic analysis of induction of labor versus expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks (PPROMEXIL trial ISRCTN29313500). American Journal of Obstetrics and Gynecology 2011;204(1 Suppl):S336. CENTRAL
Van der Ham DP, Nijhuis JG, Mol BW, Van Beek JJ, Opmeer BC, Bijlenga D, et al. Induction of labour versus expectant management in women with preterm prelabour rupture of membranes between 34 and 37 weeks (the PPROMEXIL‐trial). BMC Pregnancy and Childbirth 2007;7:11. CENTRAL
Van der Ham DP, Vijgen SMC, Nijhuis JG, Van Beek JJ, Opmeer BC, Mulder ALM, et al. Induction of labor versus expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks: a randomized controlled trial. PLoS Medicine 2012;9(4):e1001208. CENTRAL
Van der Heyden J, Willekes C, Oudijk M, Porath M, Duvekot H, Bloemenkamp KWM, et al. Behavioural and developmental outcome of neonates at 2 years of age after preterm prelabor rupture of membranes: follow up of the PPROMEXIL trial. American Journal of Obstetrics and Gynecology 2014;210(1 Suppl):S349‐50. CENTRAL
Van der Heyden JL, Willekes C, Van Baar AL, Van Wassenaer‐Leemhuis AG, Pajkrt E, Oudijk MA, et al. Behavioural and neurodevelopmental outcome of 2‐year‐old children after preterm premature rupture of membranes: follow‐up of a randomised clinical trial comparing induction of labour and expectant management. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2015;194:17‐23. CENTRAL
Willekes C. Preterm premature rupture of membranes between 34 and 37 weeks: expectant management versus induction of labour (planned trial). Current Controlled Trials (www.controlled‐trials.com) (accessed 15 February 2007)2007. CENTRAL

Van der Ham 2012b {published data only}

Tajik P, Van der Ham DP, Zafarmand MH, Hof MHP, Morris J, Franssen MTM, et al. Using vaginal Group B Streptococcus colonisation in women with preterm premature rupture of membranes to guide the decision for immediate delivery: a secondary analysis of the PPROMEXIL trials. BJOG: an international journal of obstetrics and gynaecology 2014;121:1263‐73. CENTRAL
Van der Ham D, Van der Heijden J, Opmeer B, Van Beek H, Willekes C, Mulder T, et al. Induction of labor versus expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks ‐ the PPROMEXIL‐2 trial (ISRCTN05689407). American Journal of Obstetrics and Gynecology 2012;206(Suppl 1):S8‐9. CENTRAL
Van der Ham DP, Van der Heyden JL, Opmeer BC, Mulder AL, Moonen RM, Van Beek JH, et al. Management of late‐preterm premature rupture of membranes: the PPROMEXIL‐2 trial. American Journal of Obstetrics and Gynecology 2012;207(4):276.e1‐e10. CENTRAL
Vijgen SM, Van der Ham DP, Bijlenga D, Van Beek JJ, Bloemenkamp KW, Kwee A, et al. Economic analysis comparing induction of labor and expectant management in women with preterm prelabor rupture of membranes between 34 and 37 weeks (PPROMEXIL trial). Acta Obstetricia et Gynecologica Scandinavica2014; Vol. 93, issue 4:374‐81. CENTRAL

References to studies excluded from this review

Bergstrom 1991 {published data only}

Bergstrom S. A prospective study on the perinatal outcome in Mozambican pregnant women with preterm rupture of membranes using two different methods of clinical management. Gynecologic & Obstetric Investigation 1991;32:217‐9. CENTRAL

Cararach 1994 {published data only}

Cararach V, Sentis J, Botet F, Costa J, Manau D, Arimany MC. Cervical prostaglandin E2 compared with expectant management or systematic induction in PROM with bad cervical conditions: I‐maternal results. Proceedings of 14th European Congress of Perinatal Medicine; 1994 June 5‐8; Helsinki, Finland. 1994:405. CENTRAL

Decavalas 1995 {published data only}

Decavalas G, Mastrogiannis D, Papadopoulos V, Tzingounis V. Short‐term vs long‐term prophylactic tocolysis in patients with preterm premature rupture of membranes. European Journal of Obstetrics & Gynecology and Reproductive Biology 1995;59:143‐7. CENTRAL
Decavalas G, Papadopoulos V, Tsapanos V, Tzingounis V. Tocolysis in patients with preterm premature rupture of membranes has any effect on pregnancy outcome?. International Journal of Gynecology & Obstetrics 1994;46:26. CENTRAL

El‐Qarmalawi 1990 {published data only}

El‐Qarmalawi AM, Elmardi AA, Saddik M, El‐Abdel Hadi F, Shaker SMA. A comparative randomized study of oral prostaglandin E2 (PGE2) tablets and intravenous oxytocin in induction of labor in patients with premature rupture of membranes before 37 weeks of pregnancy. International Journal of Gynecology & Obstetrics 1990;33:115‐9. CENTRAL

Fayez 1978 {published data only}

Fayez JA, Hasan AA, Jonas HS, Miller GL. Management of premature rupture of the membranes. Obstetrics & Gynecology1978; Vol. 52:17‐21. CENTRAL

Gloeb 1989 {published data only}

Gloeb DJ, O'Sullivan MJ, Beydoun SN. Relationship of the interval between spontaneous premature rupture of the membranes and inducibility of labor. Proceedings of 9th Annual Meeting of the Society of Perinatal Obstetricians; 1989 February 1‐4; New Orleans, Louisiana, USA. 1989:493. CENTRAL

Griffith‐Jones 1990 {published data only}

Griffith‐Jones MD, Tyrrell SN, Tuffnell DJ. A prospective trial comparing intravenous oxytocin with vaginal prostaglandin E2 tablets for labour induction in cases of spontaneous rupture of the membranes. Obstetrics and Gynaecology Today 1990;1(4):104‐5. CENTRAL

Haghighi 2006 {published data only}

Haghighi L. Intravaginal misoprostol in preterm premature rupture of membranes with low Bishop scores. International Journal of Gynecology & Obstetrics 2006;94(2):121‐2. CENTRAL

Lacaze 2006 {published data only}

Lacaze N. Safety and efficacy study of intentional delivery in women with preterm and prelabour rupture of the membranes (ongoing trial). www.clinicaltrials.gov (accessed 21 March 2006)2006. CENTRAL

Ladfors 1996 {published data only (unpublished sought but not used)}

Ladfors L, Mattsson LA, Eriksson M, Fall O. A randomised trial of two expectant managements of prelabour rupture of the membranes at 34 to 42 weeks. British Journal of Obstetrics and Gynaecology 1996;103:755‐62. CENTRAL
Ladfors L, Mattsson LA, Eriksson M, Fall O. A randomized prospective trial of two expectant managements of pre‐labor rupture of the membranes (PROM) at 34‐42 weeks. American Journal of Obstetrics and Gynecology 1994;170:344. CENTRAL
Ladfors L, Tessin I, Fall O, Erikson M, Matsson LA. A comparison of neonatal infectious outcome comparing two expectant managements of women with prelabor rupture of the membranes at 34‐42 weeks. American Journal of Obstetrics and Gynecology 1998;178(1 Pt 2):S197. CENTRAL

Makhlouf 1997 {published data only}

Makhlouf AM, Moemen A, Abdelaleem K, Abdelaleem H. Induction versus expectant management in preterm premature rupture of membranes. Research activities on reproductive health: annual report of Assiut University Department of Obstetrics and Gynecology November 1997. Assiut University, Faculty of Medicine, 1997:12. CENTRAL

Mateos 1998 {published data only}

Mateos D, Cararach V, Sentis J, Botet F, Figueras F, Arimany M, et al. Cervical prostaglandin E2 compared with expectant management or systematic induction in premature rupture of the membranes with bad cervical conditions. Prenatal and Neonatal Medicine 1998;1(Suppl 1):85. CENTRAL

Miodovnik 1988 {published data only}

Miodovnik M, Smith PP. Management of prelabour rupture of the membranes at 32‐36 weeks with prostaglandin present in the vaginal pool. Personal communication1988. CENTRAL

Parsons 1989 {published data only}

Parsons MT, Sobel D, Cummiskey K, Roitman J, Gall SA. Early delivery vs expectant management in patients with preterm rupture of membranes at 32‐36 weeks gestation. Proceedings of 9th Annual Meeting of the Society of Perinatal Obstetricians; 1989 Feb 1‐4; New Orleans, Louisiana, USA. 1989:391. CENTRAL

Perez 1992 {published data only}

Perez Picanol E, Vernet M, Armengol R, Perez Ares C, Lecumberri J, Gamissans O. Comparison of two different therapeutic attitudes in premature rupture of membranes. Journal of Perinatal Medicine 1992;20:353. CENTRAL

Van Heerden 1996 {published data only}

Van Heerden J, Steyn DW. Management of premature rupture of the membranes after 34 weeks' gestation ‐ early versus delayed induction of labour. South African Medical Journal 1996;86:262‐6. CENTRAL

Pasquier 2006 {published data only}

Pasquier JC, Bujold E, Mellie G. Preterm premature rupture of membranes: is there an optimal gestational age for delivery?. Obstetrics & Gynecology 2005;105(6):1484‐5. CENTRAL
Pasquier JC, Claris O, Rabilloud M, Picaud JC, Moret S, Ecochard R, et al. Feeling and motivation of women to participate in a randomized control trial in perinatality. American Journal of Obstetrics and Gynecology 2006;195(6 Suppl 1):S69. CENTRAL

Arias 1982

Arias F, Tomich P. Etiology and outcome of low birthweight and preterm infants. Obstetrics & Gynecology 1982;338:663‐70.

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Engle 2007

Engle WA, Tomashek KM, Wallman C. Late preterm infants: a population at risk. Pediatrics 2007;120:1390‐401.

Engle 2008

Engle WA, Kominiarek MA. Late preterm infants, early term infants, and timing of elective deliveries. Clinics in Perinatology 2008;35:325‐41.

Gaudet 2001

Gaudet L, Smith GN. Cerebral palsy and chorioamnionitis: the inflammatory cytokine link. Obstetrical and Gynecological Survey 2001;56(7):433‐6.

Gonen 1989

Gonen R, Hannah ME, Milligan JE. Does prolonged preterm premature rupture of the membranes predispose to abruptio placentae?. Obstetrics & Gynecology 1989;74(3):347‐50.

Hannah 1996

Hannah ME, Ohlsson A, Farine D, Hewson SA, Hodnett ED, Myhr TL, et al. Induction of labor compared with expectant management for prelabor rupture of the membranes at term. New England Journal of Medicine 1996;334(16):1005‐10.

Harding 2001

Harding JE, Pang JM, Knight DB, Liggins GC. Do antenatal corticosteroids help in the setting of preterm rupture of membranes?. American Journal of Obstetrics and Gynecology 2001;184:131‐9.

Higgins 2003

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.

Higgins 2011

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Jones 2000

Jones SC, Brost BC, Brehm WT. Should intravenous tocolysis be considered beyond 34 weeks' gestation?. American Journal of Obstetrics and Gynecology 2000;183(2):356‐60.

Kenyon 2001

Kenyon S, Taylor DJ, Tarnow‐Mordi W. Broad spectrum antibiotics for preterm, prelabour rupture of the fetal membranes: the ORACLE I randomised trial. Lancet 2001;357:979‐88.

Kenyon 2003

Kenyon S, Boulvain M, Neilson J. Antibiotics for preterm premature rupture of the membranes. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: 10.1002/14651858.CD001058]

Lee 2001

Lee T, Silver H. Etiology and epidemiology of preterm premature rupture of the membranes. Clinical Perinatology 2001;28:721‐34.

Lewis 1996

Lewis DF, Futayyeh S, Towers CV, Asrat T, Edwards MS, Brooks GG. Preterm delivery from 34‐37 weeks gestation: is respiratory distress syndrome a problem?. American Journal of Obstetrics and Gynecology 1996;174(2):525‐8.

Major 1995

Major CA, de Veciana M, Lewis DF, Morgan MA. Preterm premature rupture of the membranes and abruptio placentae: is there an association between these pregnancy complications?. American Journal of Obstetrics and Gynecology 1995;172(2):672‐6.

Mercer 2000

Mercer BM, Goldenberg RL, Meis PJ, Moawad AH, Shellhaas C, Das A, et al. The preterm prediction study: prediction of preterm premature rupture of the membranes through clinical findings and ancillary testing. American Journal of Obstetrics and Gynecology 2000;183:738‐45.

Mercer 2003

Mercer BM. Preterm premature rupture of the membranes. Obstetrics & Gynecology 2003;101(1):178‐93.

Mercer 2005

Mercer BM. Preterm premature rupture of the membranes: current approaches to evaluation and management. Obstetrics and Gynecology Clinics of North America 2005;32:411‐28.

Middleton 2017

Middleton P, Shepherd E, Flenady V, McBain RD, Crowther CA. Planned early birth versus expectant management (waiting) for prelabour rupture of membranes at term (37 weeks or more). Cochrane Database of Systematic Reviews 2017, Issue 1. [DOI: 10.1002/14651858.CD005302.pub3]

Neerhof 1999

Neerhof MG, Cravello C, Haney EI, Silver RK. Timing of labor induction after premature rupture of membranes between 32 and 36 weeks gestation. American Journal of Obstetrics and Gynecology 1999;180(2):349‐52.

RevMan 2014 [Computer program]

The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.

Roberts 2006

Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database of Systematic Reviews 2006, Issue 3. [DOI: 10.1002/14651858.CD004454.pub2]

Robertson 1992

Robertson PA, Sniderman SH, Laros RK, Cowan R, Heilbron D, Goldenberg RL, et al. Neonatal morbidity according to gestational age and birth weight from five tertiary care centers in the United States, 1983 through 1986. American Journal of Obstetrics and Gynecology 1992;166:1629‐45.

Seo 1992

Seo K, McGregor JA, French JI. Preterm birth is associated with increased risk of maternal and neonatal infection. Obstetrics & Gynecology 1992;79:75‐80.

Sterne 2011

Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Wu 2000

Wu YW, Colford JM. Chorioamnionitis as a risk factor for cerebral palsy: a meta‐analysis. JAMA 2000;284(11):1417‐24.

References to other published versions of this review

Buchanan 2010

Buchanan SL, Crowther CA, Levett KM, Middleton P, Morris J. Planned early birth versus expectant management for women with preterm prelabour rupture of membranes prior to 37 weeks' gestation for improving pregnancy outcome. Cochrane Database of Systematic Reviews 2010, Issue 3. [DOI: 10.1002/14651858.CD004735.pub3]

Characteristics of studies

Characteristics of included studies [ordered by study ID]

Cox 1995

Methods

RCT

Duration of study: May 1991‐30 April 1994

Participants

Setting: Parkland Hospital, Dallas, Texas, USA

Participants: 129 women with confirmed premature rupture of the membranes between 30‐34 weeks' gestation; 1 twin pair in each of early delivery and expectant management group resulting in a total of 131 babies:

  • 61 women were randomised to early delivery

  • 68 women were randomised to expectant management

Inclusion criteria

  • Preterm ruptured membranes at 30‐34 weeks' gestation

  • Temperature less than 37.8°C

  • No labour

  • No maternal or fetal complications necessitating delivery

Exclusion criteria

  • Active labour

  • Chorioamnionitis defined as a temperature greater than 37.9°C with either uterine tenderness or maternal tachycardia

  • Maternal hypertension

Interventions

Intervention: oxytocin labour stimulation if the fetus was cephalic; caesarean section was performed for all other presentations

Control: expectant management

  • Maternal observations and fetal heart rate recorded every 8 h

  • Electronic fetal heart rate and uterine activity monitoring was performed for 1 h each d until delivery

  • Hospitalisation until delivery

  • Criteria for delivery included:

    • spontaneous labour;

    • fever;

    • abnormal fetal heart rate

Corticosteroids, tocolysis and antibiotics were not used

Vaginal examinations were not performed in the absence of labour

Outcomes

Maternal

  • Admission to delivery interval

  • Labour induction

  • Caesarean delivery

  • Chorioamnionitis

Fetal

  • Gestational age at delivery

  • Respiratory distress:

    • none

    • halo

    • ventilator

  • Intracranial haemorrhage

  • Necrotising enterocolitis

  • Sepsis: did not specify whether positive culture required

  • Duration of time spent in special care nursery

  • Stillbirths

  • Neonatal deaths

Notes

  • Gestational age: determined by menstrual history, timing of first auscultation of fetal heart sounds, fundal height or ultrasound examination.

  • Ruptured membranes was diagnosed when amniotic fluid was visualised by sterile speculum examination draining from the cervical os.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Random number table with group allocation pre‐determined

Allocation concealment (selection bias)

Unclear risk

Sequentially numbered sealed envelopes. Not stated if envelopes were opaque or not

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Not specified

Incomplete outcome data (attrition bias)
All outcomes

Low risk

No losses to follow‐up reported
No post‐randomisation exclusions

Selective reporting (reporting bias)

Unclear risk

Outcomes only reported in results. Not pre‐specified

Other bias

Low risk

None noted

Eroiz‐Hernandez 1997

Methods

RCT

Duration of study: November 1992‐October 1993

Participants

Setting: Perinatology Department, Centro Medico Nacional, IMSS, Torreon, Coah, Mexico

Participants: 58 women with PROM between 28‐34 weeks of gestation

  • 30 women were randomised to early delivery

  • 28 women were randomised to expectant management

Inclusion criteria

  • Preterm ruptured membranes between 28‐34 weeks' gestation

  • Amniotic liquid index > 5 cm

  • A negative culture of amniotic liquid obtained by amniocentesis

Exclusion criteria

  • Women undergoing labour

  • Positive fetal lung maturity tests (tap*, clements* and 650 nm spectrophotometry)

Interventions

Control: managed with short‐term delivery with the application of a fetal lung maturity protocol of 6 doses of 250 mg of intravenous aminophylline every 8 h. Delivered according to obstetric characteristics of each woman

Treatment: managed with the same lung maturity protocol as the controls, but repeating weekly if possible

  • All participants had leukocyte counts every 3 d and daily biophysical profile

  • Antibiotics not given prophylactically

  • Tocolytics used for management of uterine contractions

  • Participant delivered if signs of chorioamnionitis

Outcomes

Maternal

  • Chorioamnionitis, defined by 15,000 leukocytes in maternal blood at the start of the study or a 50% increase from baseline reading, body temperature > 37.5°C, abdominal pain or a fetal heart rate of > 160 beats/minute without apparent cause

  • Caesarean section

  • Days between randomisation and delivery

  • Causes of caesarean section

  • Causes of delivery

Fetal

  • Hyaline membrane disease: diagnosed by prematurity, neonatal asphyxia, progressive onset of respiratory insufficiency, thorax X‐rays with the presence of peripheral aerial bronchogram with reticulogranular infiltrates and gasometric respiratory acidosis followed by mixed acidosis

  • Neonatal septicaemia diagnosed if the following were present: general poor condition, paleness, jaundice, petechia, equimosis, hypoactivity or irritability, seizure, hepatosplenomegaly, abnormal bleeding, vomit, diarrhoea, gastric residual and hypothermia or fever, leukocytosis (> 25,000), leucopenia (< 5000), total bands (> 500), neutropenia (< 1500), Shilling index of > 0.2 and thrombocytopenia (< 100,000), 1 of 3 lumbar puncture blood culture positive with: > 20 cells, hypoglycorrhaghia (< 40 mg/dL), hyperproteinrhachia (> 280 mg/dL). Sepsis also diagnosed if sepsis protocol started with clinical suspicion without positive culture and clinical improvement after antibiotics

  • Birthweight

  • Apgar scores at 1 min and 5 min

  • Silverman score at 1 min and 5 min

  • Perinatal death

  • Muscoluskeletal abnormalities

  • Amniotic band syndrome

Notes

Gestational age calculated by date of last menstrual period or ultrasound PROM diagnosis performed by Tamiere* procedure (maneuver), cristallography, or the flame test

*The authors are unsure of what this procedure is, although this may be an error in translation.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Random number table

Allocation concealment (selection bias)

Unclear risk

Not specified

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Not specified

Incomplete outcome data (attrition bias)
All outcomes

High risk

Results inconsistent with number randomised. Incomplete data not recorded

Selective reporting (reporting bias)

High risk

Outcomes only reported in results. Not pre‐specified. Although inclusion criteria was singleton pregnancy only, results for caesarean section indicate 2 sets of twins in each group. This was not reported.

Other bias

Low risk

None noted

Garite 1981

Methods

RCT
Duration of study: May 1977‐July 1980

Participants

Setting: Obstetric services at the University of California Irvine Medical Center and Women's Hospital Memorial Medical Center of Long Beach, Orange County, California, USA

Participants: 160 women; 80 women in early delivery group and 80 women in expectant management group

Inclusion criteria

  • Women with preterm premature rupture of the membranes

  • 28‐34 weeks' gestation

Exclusion criteria

  • Fetal distress

  • Chorioamnionitis

  • Mature L/S ratio

  • Advanced labour

Prior to randomisation all women

  • Monitored with an external fetal heart rate monitor for a minimum of 30 min

  • Ultrasound examination performed where BPD determined.

  • Amniocentesis performed for L/S ratio, gram stain and culture

  • Management was delayed until results were known ‐ "usually 3 to 4 hours"

  • If the L/S ratio was 1.8:1 or greater or if the gram stain demonstrated bacteria the fetus was not included in the study

Interventions

Intervention: 80 women were randomised to corticosteroids and delivery 48 h after treatment with steroids

  • This included betamethasone 12 mg intramuscularly 2 doses 24 h apart

  • Tocolysis used when contractions occurred

  • Delivery was after 48 h by discontinuing the tocolytic and either induction of labour with oxytocin or caesarean section for obstetric indications

Control: 80 women were randomised to expectant management

  • Delivered when labour, chorioamnionitis or fetal distress evident

Criteria for delivery for women in the expectant management group included:

  • labour

  • chorioamnionitis

  • fetal distress

Corticosteroids and tocolysis used in early delivery group. Prophylactic antibiotics not used.

Vaginal examinations were not performed in the absence of labour.

Outcomes

Maternal

  • Admission to delivery time

  • Caesarean section

  • Chorioamnionitis: fever ≥ 100.4°F in the absence of other explanations

  • Endometritis

  • Wound infection

  • Urinary tract infection

  • Duration of postpartum hospital stay

Fetal

  • Birthweight

  • Gestational age

  • Respiratory distress

    • made when clinical signs and chest X‐ray film were confirmatory

    • infant required > 24 h/oxygen therapy

    • severe RDS: requiring a ventilator

  • Sepsis: not stated as to whether a positive culture required for diagnosis

  • Meningitis

  • Ophthalmitis

  • Pneumonia

  • Necrotising enterocolitis

  • Fetal death

  • Neonatal death

Notes

  • Gestational age determined by menstrual history and examination, or by a BPD on presentation

  • Rupture of the membranes was documented by sterile speculum examination visualising amniotic fluid pooling in the posterior vaginal vault, alkaline pH by Nitrazine paper and ferning on microscopic examination of fluid from the posterior vaginal fornix.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Randomisation schema not defined

Allocation concealment (selection bias)

Unclear risk

Not defined

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Radiologists (for reviewing X‐rays prior to diagnosis of hyaline membrane disease) were blinded as to treatment allocation. However it was not mentioned if all other analysts were blinded to treatment.

Incomplete outcome data (attrition bias)
All outcomes

High risk

No losses to follow‐up reported. However, 1 fetal death in expectant management group removed from denominator of neonatal outcomes

Selective reporting (reporting bias)

Unclear risk

Outcomes only reported in results. Not pre‐specified

Other bias

Low risk

None noted

Iams 1985

Methods

RCT

Duration of study: September 1979‐November 1982

Participants

Setting: Ohio State University Hospitals, Ohio, USA

Participants: 73 women; 38 early delivery, 35 expectant management

Inclusion criteria

  • Preterm premature rupture of the membranes

  • 28‐34 weeks' gestation

Exclusion criteria

  • Women with mature L/S ratios (greater than 2:1 or more) were delivered

  • Active labour

  • Infection

  • Twin pregnancy

Interventions

Intervention: corticosteroids, tocolysis and delivery 48‐72 hours after initiation of steroid treatment

  • Hydrocortisone 500 mg intravenously every 8 h for 4 doses

  • Tocolysis included either magnesium sulphate, terbutaline or ritodrine

  • Caesarean section for obstetric indications

Control: expectant management.

  • Admission to hospital initially

  • Serial observations including vital signs, abdominal examination, WBC counts

  • Delivery after labour, chorioamnionitis or fetal distress occurred

  • Outpatient management at discretion of managing clinician

Criteria for delivery of women in the expectant management group included

  • labour

  • chorioamnionitis

  • fetal distress

Corticosteroids and tocolysis given to early delivery group. Prophylactic antibiotics not given.

Vaginal examinations were not performed in the absence of labour.

Outcomes

Maternal

  • Ruptured membranes to delivery time

  • Caesarean section

  • Chorioamnionitis

  • Endometritis: temp > 100.6°F on 2 readings 6 or more h apart > 24 h postpartum

  • Duration of hospitalisation

Fetal

  • Birthweight

  • Duration of admission to delivery

  • Apgar score

  • Duration of total hospitalisation

  • Respiratory distress: required > 24 h oxygen therapy with compatible clinical and chest X‐ray findings

    • duration of time on ventilator

    • duration of time requiring oxygen therapy

  • Sepsis: required a positive culture for diagnosis

  • Leukopenia

  • Jaundice

  • Perinatal mortality

Notes

  • Gestational age defined by obstetric history and sonography

  • Ruptured membranes defined by visualisation of amniotic fluid pooled in the posterior vaginal fornix on sterile speculum examination or positive Nitrazine and ferning tests.

  • An L/S ratio is a ratio used to determine fetal pulmonary maturity and therefore, the risk of neonatal RDS if the fetus is delivered prematurely. It is found by testing the amniotic fluid and when the fetal lungs are mature, lecithin exceeds sphingomyelin by 2 to 1.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Random number table

Allocation concealment (selection bias)

Unclear risk

Not defined

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Not defined

Incomplete outcome data (attrition bias)
All outcomes

High risk

Losses to follow‐up: 3 women in expectant management group delivered at another hospital and were excluded from analysis.

Post‐randomisation exclusions: 1 neonate with congenital anomalies was excluded post delivery, 1 mother and her baby were excluded for failure to complete steroid therapy.

Selective reporting (reporting bias)

Unclear risk

Outcomes only reported in results. Not pre‐specified

Other bias

Low risk

None noted

Koroveshi 2013

Methods

Prospective RCT

Duration of study: March 2008‐October 2011

Participants

Setting: Albania

Participants: 307 pregnant women, 157 in planned early birth group and 150 to expectant management group

Inclusion criteria

  • Women with preterm premature rupture of the membranes

  • 34‐37 weeks' gestation

Exclusion criteria

  • Not defined

Interventions

Planned early birth versus expectant management ‐ not defined

Outcomes

Maternal

  • Caesarean section

Fetal

  • Neonatal sepsis

  • RDS

Notes

Abstract only. Limited data available

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Unclear risk

Method not specified

Allocation concealment (selection bias)

Unclear risk

Not specified

Blinding of participants and personnel (performance bias)
All outcomes

Unclear risk

Blinding not possible due to intervention. However the risk was unclear as assessment criteria for outcomes was not mentioned

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Not specified

Incomplete outcome data (attrition bias)
All outcomes

Unclear risk

Not specified

Selective reporting (reporting bias)

High risk

Only 3 outcomes as well as secondary unspecified outcomes reported in abstract. Full paper not published

Other bias

Unclear risk

As this is an abstract publication only, cannot determine the overall risk of bias

Mercer 1993

Methods

RCT

Duration of study: 1 March 1991‐31 July 1992

Participants

Setting: University of Tennessee, Memphis, USA

Participants: 93 women

  • 46 women were randomised to induction of labour

  • 47 women were randomised to expectant management

Inclusion criteria

  • Confirmed premature rupture of the membranes at 32 weeks‐36 weeks 6 days

  • Amniotic fluid testing suggestive of fetal pulmonary maturity

Exclusion criteria

  • Cervical dilatation greater than 2 cm

  • Persistent regular contractions or progressive labour

  • Blood or meconium‐stained amniotic fluid

  • Suspected chorioamnionitis

  • Any maternal or fetal contraindication to expectant management

  • Women with fetuses with intrauterine growth restriction

  • Women with fetuses with congenital malformations

  • A non‐reassuring fetal heart rate tracing (defined as recurrent decelerations, heart rate greater than 160 beats per minute, or the absence of heart rate accelerations)

Interventions

Intervention: intravenous oxytocin infusion

Control: expectant management

  • This included 12 h of continuous fetal heart rate monitoring

  • Observations performed every 8 h

  • Women restricted to bed rest

  • Criteria for delivery included

    • progressive labour

    • chorioamnionitis (defined as a temperature > 100.4°F plus any 2 of the following: fetal or maternal tachycardia, uterine contractions or tenderness, foul smelling amniotic fluid in the absence of other identifiable cause)

    • non‐reassuring fetal heart rate pattern including persistent fetal tachycardia or recurrent deceleration and positive cultures for Neisseria gonorrhoeae or GBS

Corticosteroids, tocolysis and prophylactic antibiotics not used

Vaginal examinations not performed in the absence of labour

Outcomes

Maternal

  • Latency from randomisation to labour

  • Latency from randomisation to delivery

  • Duration of maternal hospital stay

  • Chorioamnionitis: T > 100.4°F plus 2 of the following:

    • fetal or maternal tachycardia

    • uterine contractions or tenderness

    • foul‐smelling amniotic fluid in the absence of other identifiable cause

  • Caesarean delivery

  • Postpartum infection requiring antibiotics

Fetal

  • Neonatal sepsis: required a positive culture for diagnosis

    • subgrouped into suspected and confirmed sepsis:

      • suspected neonatal sepsis: clinical findings suggestive of neonatal infection or persistent leucopenia with a WBC count < 4000/mm3 or a C‐reactive protein level elevated greater than 0.6;

      • confirmed neonatal sepsis: infants with symptoms of sepsis and positive blood cultures

  • Abnormal fetal heart rate pattern

  • Birthweight

  • Apgar scores

  • Respiratory distress:

    • required oxygen therapy (at least 40%) at least 24 h in absence of other identifiable cause

  • Pneumonia

  • Necrotising enterocolitis

  • Intraventricular haemorrhage

  • Duration of neonatal hospital stay

  • Mortality

Notes

  • Gestational age: determined clinically on the basis of menstrual history, earliest ultrasound examination and first clinical assessment

  • Ruptured membranes diagnosed by: visualisation of amniotic fluid passing from the cervical os on sterile speculum examination or the presence of a pool of fluid in the posterior vaginal fornix that was positive to both Nitrazine paper and ferning tests

  • Fetal pulmonary maturity was determined on pooled vaginal fluid (foam stability index ≥ 47 considered mature), an amniocentesis was performed in the absence of adequate vaginal fluid.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Computer‐generated random number tables

Allocation concealment (selection bias)

Unclear risk

Not clearly defined. Stated that "blinded" random number tables were used, but no further explanation was given as to what this entailed.

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Neonatologists were not blinded to the perinatal clinical course. It was not specified whether the assessors of maternal outcomes were blinded to their clinical course.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

No losses to follow‐up or post‐randomisation exclusions

Selective reporting (reporting bias)

Unclear risk

Outcomes only reported in results. Not pre‐specified

Other bias

Low risk

None noted

Morris 2016

Methods

Multi‐centre, international RCT

Duration of study: May 2004‐June 2013

Participants

Setting: 65 tertiary hospitals in 11 countries (Australia, Argentina, Brazil, Egypt, New Zealand, Norway, Poland, Romania, South Africa, UK, Uruguay)

Participants: 1835 women

  • 923 women were randomised to induction of labour

  • 912 women were randomised to expectant management

Inclusion criteria

  • Over 16 years of age

  • Singleton pregnancy

  • Clinically suspected ruptured membranes between 34 weeks‐36 + 6 weeks' gestation

Exclusion criteria

  • Established labour

  • Chorioamnionitis

  • Meconium staining

  • Any other contraindications to continuing the pregnancy

Interventions

Intervention

  • Delivery scheduled as close to randomisation as possible and preferably within 24 h

  • Mode of birth was determined by usual obstetric indications

Control: expectant management

  • Inpatient or outpatient management according to local guidelines

Criteria for delivery included

  • Spontaneous labour

  • At term

  • When the attending clinician felt that birth was mandated according to usual indications

Antibiotics were prescribed according to local protocols.

Laboratory testing and other management was per usual hospital practice.

Placental histology was encouraged but not uniformly requested.

Outcomes

Maternal

  • Antepartum or intrapartum haemorrhage

  • Antepartum or postpartum thrombosis

  • Cord prolapse

  • Postpartum treatment with antibiotics

  • Intrapartum fever (pyrexia ≥ 38.5°C)

  • Postpartum haemorrhage (> 1000 mL)

  • Mode of delivery

  • Onset of labour

  • Duration of hospitalisation (total days from randomisation to delivery, and from delivery to discharge or transfer)

  • Chorioamnionitis among the women with expectant management

Fetal

  • Definite or probable neonatal sepsis

    • Definite:

      • positive culture of a known pathogen from blood or CSF

      • baby treated with antibiotics for 5 or more days (or died before 5 days)

      • presence of clinical signs of infection: respiratory distress (requiring ventilation, continuous positive airway pressure or supplemental oxygen for more than 1 h), apnoea, lethargy, abnormal level of consciousness, circulatory compromise (including hypotension, poor perfusion, need for inotropic support or volume expansion) and/or temperature instability (temperature < 36°C or ≥ 38°C);

      • for organisms of low virulence and/or high likelihood of skin contamination of the blood culture, both a positive blood culture and an abnormal full blood count (WCC < 5 x 109/L or > 30 x 109/L, platelet count < 100,000, neutrophil count < 1.5 x 109/L or raised immature to total neutrophil ratio (I:T ratio > 0.2)) or abnormal C‐reactive protein > 10 mg/L were required

    • Probable:

      • presence of clinical signs where the baby was treated with antibiotics for 5 or more days together with 1 or more of: an abnormal FBC; abnormal C‐reactive protein; positive GBS antigen on bladder tap urine, blood or CSF; elevated CSF WCC5 (CSF WCC > 100 x 106/L); growth of a known virulent pathogen (e.g. GBS,E. coli, Listeria) from surface swab; or a histologic diagnosis of pneumonia in an early neonatal death

  • Composite neonatal morbidity and mortality indicator (sepsis, mechanical ventilation > 24 h, stillbirth or neonatal death)

  • Respiratory distress

  • Perinatal mortality

  • Pneumonia

  • Mechanical ventilation (intermittent positive pressure ventilation, continuous positive airway pressure or high frequency ventilation) for greater than 24 h

  • Duration of stay in a neonatal intensive or special care unit

  • Duration of stay in hospital

  • Birthweight

  • Apgar score ≤ 7 at 5 min

  • Antibiotics in the first 48 h

  • Lumbar puncture

  • Circulatory compromise requiring arterial line

  • Fluid bolus or inotropic support

  • Receiving breast milk at discharge (exclusive or mixed feeding)

Notes

  • Women who presented with ruptured membranes earlier in pregnancy became eligible on reaching 34 weeks' gestation.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

A computer‐generated randomisation schedule was used in a 1:1 ratio in balanced blocks of variable size, stratified by centre.

Allocation concealment (selection bias)

Low risk

A central telephone service was used for randomisation allocation.

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

The primary outcome was determined by comprehensive review of the neonatal data by a central adjudication committee masked to the treatment allocation.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

All analyses were by intention‐to‐treat. No participants were excluded from the primary intention‐to‐treat analysis due to protocol violations.

Selective reporting (reporting bias)

Low risk

All a‐priori outcomes were reported on.

Other bias

Low risk

None noted

Naef 1998

Methods

RCT

Duration of study: 1992‐1994

Participants

Setting: University of Mississippi Medical Center, Jackson, Mississippi, USA

Participants: 120 singleton pregnancies

  • 57 women were randomised to early delivery

  • 63 women were randomised to expectant management

Inclusion criteria

  • Cephalic presentation

  • Singleton pregnancy

  • 34 weeks' gestation to 36 weeks 6 days gestation

  • Preterm premature rupture of the membranes

Exclusion criteria

  • Non‐cephalic presentation

  • Fetal distress

  • Labour on admission

  • Chorioamnionitis

  • Maternal medical conditions including hypertension, diabetes, active genital herpes, placenta praevia

  • Severe fetal anomalies

  • Meconium‐stained amniotic fluid

Interventions

Intervention: induction of labour with intravenous oxytocin

Control: expectant management

  • Observations and a fetal heart rate assessment every 8 h

  • Bed rest and hospitalised until delivery

  • Treatment with ampicillin 2 g intravenously was carried out for all participants for GBS prophylaxis

  • Criteria for delivery included:

    • non‐reassuring fetal status (recurrent decelerations or persistent tachycardia)

    • initiation of labour

    • signs of clinical chorioamnionitis (defined in the absence of other causes of pyrexia as a temperature > 100.4 °F with either uterine tenderness, leucocytosis, maternal or fetal tachycardia or a foul smelling vaginal discharge)

Corticosteroids and tocolysis not used. Routine antibiotic prophylaxis for all women

Vaginal examinations not performed in the absence of labour

Outcomes

Maternal

  • Admission to delivery interval

  • Chorioamnionitis: temperature > 100.4 °F with either uterine tenderness (or contractions), leuko‐cytosis, maternal or fetal tachycardia, or a foul‐smelling vaginal discharge

  • Postpartum endometritis: temperature > 100.4 °F after the first 24 postpartum hours with associated uterine tenderness

  • Duration of hospital stay

  • Mode of delivery

Fetal

  • Birthweight

  • Apgar scores

  • Cord pH

  • Neonatal nursery admission

  • Respiratory distress

  • Mechanical ventilation

  • Sepsis: positive culture required for diagnosis

  • Intraventricular haemorrhage

  • Patent ductus arteriosus

  • Broncopulmonary dysplasia

  • Duration of hospital stay

  • Stillbirth

  • Neonatal death

Notes

  • Gestational age was confirmed by a reliable last menstrual period, early ultrasound or first trimester pelvic examination

    • In the absence of certain dates an ultrasound estimate of fetal weight ≥ 1800 g and ≤ 2500 g was used as an entry criteria.

  • Ruptured membranes was confirmed by visualisation of pooling of fluid in the posterior vaginal fornix on sterile speculum examination or ferning under microscopic review in addition to a positive Nitrazine test.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Computer‐generated random number cards

Allocation concealment (selection bias)

Unclear risk

Opaque sealed envelopes but did not state if envelopes were sequentially numbered

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Neonatologists were not blinded to the perinatal clinical course. It was not specified whether the assessors of maternal outcomes were blinded to their clinical course.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

No losses to follow‐up
No post‐randomisation exclusions

Selective reporting (reporting bias)

Low risk

All a‐priori outcomes were reported on

Other bias

Low risk

None noted

Nelson 1985

Methods

RCT
Duration of study: not specified

Participants

Setting: Wake Forest University Medical Center, North Carolina, USA

Participants: 68 women

  • 22 women randomised to steroid and early delivery group

  • 22 women randomised to no‐steroid and early delivery group

  • 24 women randomised to no‐steroid and expectant group

Inclusion criteria

  • Women with preterm premature rupture of the membranes

  • 28‐34 weeks' gestation

Exclusion criteria

  • Evidence of fetal distress

  • Active labour

  • Cervix > 3 cm dilated

  • Sensitivity to tocolysis

  • History of preterm premature rupture of the membranes > 24 h

  • Existing infection

Interventions

Intervention: included 2 groups

Group 1. Steroid group who received intramuscular betamethasone 6 mg or 12 mg on admission and another dose 12 h later

  • Ritodrine or terbutaline tocolysis used for a minimum of 24 h after the first steroid dose

  • Delivery between 24‐48 h after initial PROM and after 24 h of steroid therapy

  • Caesarean section performed for obstetric indications

Group 2. No‐steroid group who received similar treatment to group 1 except no steroids were given

Control: expectant management

  • 24 women randomised to expectant group

  • Received no tocolytics or steroids

  • Caesarean section for usual obstetric indications

Criteria for delivery in the expectant group not specified

Corticosteroids and tocolysis used for early delivery group. Prophylactic antibiotics not used.

Not specified as to whether digital vaginal examinations were performed

Outcomes

Maternal

  • Duration of latency period

  • Maximum temperature

  • Maternal sepsis: T > 37.7°C on 2 occasions at least 6 h apart, uterine tenderness and a rising WBC

  • Use of tocolysis

  • Mode of delivery

Fetal

  • Birthweight

  • Duration of hospitalisation

  • Respiratory distress:

    • none

    • mild

    • moderate

    • severe

  • Neonatal sepsis: positive culture required for diagnosis

  • Neonatal deaths

Notes

  • Gestational age confirmed by ultrasound on admission

  • Ruptured membranes diagnosed by ferning under microscopy, Nitrazine test and/or visualisation of pooling of amniotic fluid in the posterior fornix or the vagina at the time of sterile speculum examination

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Randomised cards were used. Participants were randomly assigned by drawing a sealed envelope from a group of randomised cards, it did not state how the randomisation sequence was generated.

Allocation concealment (selection bias)

Unclear risk

Sealed envelopes but did not state if opaque or sequentially numbered

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

Not specified

Incomplete outcome data (attrition bias)
All outcomes

Low risk

No losses to follow‐up
No post‐randomisation exclusions

Selective reporting (reporting bias)

Low risk

All a‐priori outcomes were reported on

Other bias

Low risk

None noted

Spinnato 1987

Methods

RCT
Duration of study: 1 June 1983‐15 November 1984

Participants

Setting: E.H. Crump Women's Hospital and Perinatal Center, Memphis, Tennessee, USA

Participants: 47 women

  • 26 women randomised to early delivery

  • 21 women randomised to expectant management

Inclusion criteria

  • 25‐36 weeks' gestation

  • Preterm premature rupture of the membranes

  • Fetal pulmonary maturity demonstrated on amniotic fluid (an L/S ratio of 2 or more or a Foam stability index of 47 or more)

Exclusion criteria

  • Spontaneous labour at presentation

  • Chorioamnionitis

Interventions

Intervention: early delivery either by induction of labour with oxytocin or caesarean section for all non‐vertex presentations

Control: expectant management

  • External electronic fetal monitoring performed for 8‐12 h

  • Bed rest for as long as amniotic fluid leakage continued

  • Hospital discharge permitted at the discretion of the attending physician

  • Monitored with serial temperature, pulse, fetal heart rate, WBC and differential counts

Criteria for delivery in the expectant group of women

  • Labour

  • Fetal distress

  • Chorioamnionitis

Corticosteroids, tocolysis and prophylactic antibiotics not used

Vaginal examinations not performed in the absence of labour

Outcomes

Maternal

  • Time from rupture of membranes to labour

  • Time from rupture of membranes to delivery

  • Duration of labour

  • Delivery by caesarean section

  • Chorioamnionitis: maternal fever (38°C on 2 occasions or a single reading on 38.3°C) with foul‐smelling vaginal discharge and uterine tenderness, or when no other source for maternal fever could be identified

  • Endometritis: fever (excluding during 1st 24 h postpartum) plus uterine tenderness or foul‐smelling lochia

Fetal

  • Birthweight

  • Apgar score < 7 at 5 min

  • Neonatal duration of hospitalisation

  • Hyaline membrane disease

  • Transient pulmonary insufficiency (includes respiratory insufficiency of prematurity, RDS, and transient tachypnoea of the newborn)

  • Need for mechanical ventilation > 24 h

  • Need for oxygen therapy > 3 d

  • Infection

  • Sepsis: not specified if positive culture required for diagnosis

  • Pneumonia

  • Meningitis

  • Necrotising enterocolitis

  • Intracranial haemorrhage

  • Seizures

  • Perinatal death

Notes

  • Gestational age determined by "best clinical estimate" including ultrasound examination on admission

  • Ruptured membranes diagnosed by speculum examination demonstrating pooled amniotic fluid in the vaginal vault or alkaline pH by Nitrazine paper and microscopic ferning of air dried vaginal vault fluid

  • Fetal pulmonary maturity required

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

Sequential sealed envelope odd‐even random numbers

Allocation concealment (selection bias)

Unclear risk

Sealed envelopes, did not specify if opaque or sequentially numbered

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Unclear risk

  • Obstetricians not blinded to maternal allocation group

  • Neonatologists blinded to perinatal clinical course

However, did not mention if outcome assessors were blinded

Incomplete outcome data (attrition bias)
All outcomes

High risk

Losses to follow‐up: no losses to follow‐up

Post‐randomisation exclusions: 7 women for preterm labour, 4 women for "protocol violations", and 4 other women with unspecified reason

Selective reporting (reporting bias)

Unclear risk

Outcomes only reported in results. Not pre‐specified

Other bias

Low risk

None noted

Van der Ham 2012a

Methods

Multi‐centre, parallel, open‐label RCT
Duration of study: January 2007‐September 2009

Participants

Setting: 8 academic and 52 non‐academic hospitals in the Netherlands

Participants: 532 women

  • 266 women randomised to early birth (included 268 babies)

  • 266 women randomised to expectant management (included 270 babies)

Inclusion criteria

  • Singleton or twin pregnancy with PPROM between 34 and 36 + 6 weeks' gestation who were not in labour within 24 h of PPROM

  • PPROM had to be diagnosed after 26 + 0 weeks

Exclusion criteria

  • Monochorionic multiple pregnancy

  • Abnormal (non‐reassuring) cardiotocogram

  • Meconium‐stained amniotic fluid

  • Signs of intrauterine infection

  • Major fetal anomalies

  • Haemolysis, elevated liver enzymes, and low platelets (HELLP syndrome)

  • Severe pre‐eclampsia

Interventions

Intervention: induction of labour within 24 h after randomisation. Induction performed according to national guidelines. After vaginal examination, labour induced with either prostaglandin or oxytocin, or caesarean section performed as soon as feasible in case of planned caesarean

Control: expectant management

  • Monitored according to local protocol until spontaneous birth, which could be outpatient or inpatient

  • Daily maternal temperature, monitoring and twice‐weekly blood sampling for maternal leukocyte count and C‐reactive protein measurement

Criteria for delivery in the expectant group of women

  • Induced at 37 weeks according to national guidelines

  • If planned caesarean section, caesarean section performed as soon as labour commenced

  • Induction of labour < 37 weeks if clinical signs of infection or other fetal or maternal indication for birth

Tocolysis and prophylactic antibiotics used according to local protocols

Corticosteroids given in PPROM < 34 weeks' gestation

Vaginal examinations not performed in the absence of labour

Outcomes

Maternal

  • Antepartum haemorrhage

  • Uterine rupture

  • Umbilical cord prolapse

  • Signs of chorioamnionitis (defined as fever before or during labour and a temperature < 37.5°C on 2 occasions more than 1 h apart before or during labour, or a temperature > 38.0°C on 1 occasion with uterine tenderness)

  • Leukocytosis

  • Maternal or fetal tachycardia (or a foul‐smelling vaginal discharge in absence of any other cause of hyperpyrexia)

  • Maternal sepsis (defined as a temperature > 38.5°C and a positive blood culture or circulatory instability requiring intensive care monitoring)

  • Thromboembolic complications

  • Urinary tract infection treated with antibiotics

  • Endometritis (defined as a temperature > 38.0°C on 2 occasions at least 1 h apart after the 1st 24 h postpartum with associated uterine tenderness)

  • Pneumonia

  • Anaphylactic shock

  • HELLP syndrome

  • Maternal death

  • Other complications

  • Total length of hospital stay

  • Admission to the ICU

  • Mode of birth

  • Need for anaesthesia

Fetal

  • Neonatal sepsis:

    • positive blood culture at birth (excluding Staph epidermidis)

    • 2 or more symptoms of infection (apnoea, temperature instability, lethargy, feeding intolerance, respiratory distress, haemodynamic instability) within 72 h after birth plus 1 of the following: positive blood culture, C‐reactive protein > 20 mmol/L, positive surface cultures of a known virulent pathogen

  • RDS

  • Wet lung

  • Meconium aspiration syndrome

  • Pneumothorax/pneumomediastinum

  • Asphyxia

  • Late onset neonatal sepsis

  • Hypoglycaemia

  • Necrotizing enterocolitis

  • Hyperbilirubinaemia

  • Intraventricular haemorrhage

  • Periventricular leucomalacia

  • Convulsions

  • Other neurological abnormalities

  • Other complications

  • Intrapartum death

  • Total length of hospital stay and admission

  • Length of stay on NICU

Notes

  • Rupture of membranes was diagnosed based on history and clinical findings such as gross vaginal fluid loss in combination with other available diagnostic test methods.

  • Gestational age was based either on first trimester ultrasound scan or, in women with a regular cycle, on the first day of the last menstrual cycle if the expected date of birth differed less than 7 days from that estimated by ultrasound. In women with unknown EDD, gestational age was estimated by 2nd trimester ultrasound measurements.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

A computer‐generated randomisation schedule was used in a 1:1 ratio using a block size of 4, stratified for centre and parity.

Allocation concealment (selection bias)

Low risk

Randomisation allocation was performed on a central password‐protected web‐based application.

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

Criteria for sepsis were entered in the database and the case was judged by an independent panel of paediatricians who were unaware of the allocation of randomisation.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Data analysed on intention‐to‐treat basis. 2 participants were excluded post randomisation from the primary intention‐to‐treat analysis due to ineligibility.

Selective reporting (reporting bias)

Low risk

All a‐priori outcomes were reported on.

Other bias

Low risk

None noted

Van der Ham 2012b

Methods

Multi‐centre, parallel, open‐label RCT
Duration of study: December 2009‐January 2011

Participants

Setting: 8 academic and 52 non‐academic hospitals in the Netherlands

Participants: 195 women

  • 100 women randomised to early birth (included 100 babies)

  • 95 women randomised to expectant management (included 98 babies)

Inclusion criteria

  • Singleton or twin pregnancy with PPROM between 34 and 36 + 6 weeks' gestation who were not in labour within 24 h of PPROM

  • PPROM had to be diagnosed after 26 + 0 weeks

Exclusion criteria

  • Monochorionic multiple pregnancy

  • Abnormal (non‐reassuring) cardiotocogram

  • Meconium‐stained amniotic fluid

  • Signs of intrauterine infection

  • Major fetal anomalies

  • HELLP syndrome

  • Severe pre‐eclampsia

Interventions

Intervention: induction of labour with 24 h after randomisation. Induction performed according to national guidelines. After vaginal examination, labour induced with either prostaglandin or oxytocin, or caesarean section performed as soon as feasible in case of planned caesarean.

Control: expectant management

  • Monitored according to local protocol until spontaneous birth which could be outpatient or inpatient

  • Daily maternal temperature, monitoring and twice‐weekly blood sampling for maternal leukocyte count and C‐reactive protein measurement

Criteria for birth in the expectant group of women

  • Induced at 37 weeks according to national guidelines

  • If planned caesarean section, caesarean section performed as soon as labour commenced

  • Induction of labour < 37 weeks if clinical signs of infection or other fetal or maternal indication for birth

Tocolysis and prophylactic antibiotics used according to local protocols

Corticosteroids given in PPROM < 34 weeks' gestation

Vaginal examinations not performed in the absence of labour

Outcomes

Maternal

  • Antepartum haemorrhage

  • Uterine rupture

  • Umbilical cord prolapse

  • Signs of chorioamnionitis (defined as fever before or during labour and a temperature < 37.5°C on 2 occasions more than 1 h apart before or during labour, or a temperature > 38.0°C on 1 occasion with uterine tenderness)

  • Leukocytosis

  • Maternal or fetal tachycardia (or a foul‐smelling vaginal discharge in absence of any other cause of hyperpyrexia)

  • Maternal sepsis (defined as a temperature > 38.5°C and a positive blood culture or circulatory instability requiring intensive care monitoring)

  • Thromboembolic complications

  • Urinary tract infection treated with antibiotics

  • Endometritis (defined as a temperature > 38.0°C on 2 occasions at least 1 h apart after the 1st 24 h postpartum with associated uterine tenderness)

  • Pneumonia

  • Anaphylactic shock

  • HELLP syndrome

  • Maternal death

  • Other complications

  • Total length of hospital stay

  • Admission to the ICU

  • Mode of birth

  • Need for anaesthesia

Fetal

  • Neonatal sepsis:

    • positive blood culture at birth (excluding Staph epidermidis);

    • 2 or more symptoms of infection (apneas, temperature instability, lethargy, feeding intolerance, respiratory distress, haemodynamic instability) within 72 h after birth plus 1 of the following: positive blood culture, C‐reactive protein > 20 mmol/L, positive surface cultures of a known virulent pathogen

  • RDS

  • Wet lung

  • Meconium aspiration syndrome

  • Pneumothorax/pneumomediastinum

  • Asphyxia

  • Late onset neonatal sepsis

  • Hypoglycaemia

  • Necrotizing enterocolitis

  • Hyperbilirubinaemia

  • Intraventricular haemorrhage

  • Periventricular leucomalacia

  • Convulsions

  • Other neurological abnormalities

  • Other complications

  • Intrapartum death

  • Total length of hospital stay and admission

  • Length of stay on NICU

Notes

  • Rupture of membranes was diagnosed based on history and clinical findings such as gross vaginal fluid loss in combination with other available diagnostic test methods.

  • Gestational age was based either on first trimester ultrasound scan or, in women with a regular cycle, on the first day of the last menstrual cycle if the expected date of birth differed less than 7 days from the estimated by ultrasound. in women with unknown EDD, gestational age was estimated by 2nd trimester ultrasound measurements.

Risk of bias

Bias

Authors' judgement

Support for judgement

Random sequence generation (selection bias)

Low risk

A computer‐generated randomisation schedule was used in a 1:1 ratio using a block size of 4, stratified for centre and parity.

Allocation concealment (selection bias)

Low risk

Randomisation allocation was performed on a central password‐protected web‐based application.

Blinding of participants and personnel (performance bias)
All outcomes

Low risk

Blinding not possible due to intervention. However this was likely low risk of bias due to objective and specific assessment criteria for outcomes, where lack of blinding did not affect treatment decisions or other aspects of care.

Blinding of outcome assessment (detection bias)
All outcomes

Low risk

Criteria for sepsis were entered in the database and the case was judged by an independent panel of paediatricians who were unaware of the allocation of randomisation.

Incomplete outcome data (attrition bias)
All outcomes

Low risk

Data analysed on intention‐to‐treat basis. No participants were excluded.

Selective reporting (reporting bias)

Low risk

All a‐priori outcomes were reported on.

Other bias

Low risk

None noted

2 perinatal deaths resulting from lethal congenital abnormalities were excluded from analyses post‐randomisation.

BPD: biparietal diameter of the fetal head
CSF: cerebrospinal fluid
EDD: estimated due date
GBS: Group B Streptococcus/Streptococcal
HELLP: haemolysis, elevated liver enzymes, and low platelets
L/S: Lecithin‐sphingomyelin
NICU: neonatal intensive care unit
PPROM: preterm prelabour rupture of the membranes
RCT: randomised controlled trial
RDS: respiratory distress syndrome
WBC: white blood cells
WCC: white cell count

Characteristics of excluded studies [ordered by study ID]

Study

Reason for exclusion

Bergstrom 1991

Not a RCT

Cararach 1994

Unable to establish that all women were prior to 37 weeks' gestation.
Included women at term

Decavalas 1995

Assessed effect of tocolysis in women with PPROM. Tocolysis was used for 24 h in 1 group and until birth in the other group of women. Primary outcome was efficacy of tocolysis ‐ delivered if tocolysis failed or if complications occurred relating to tocolysis therapy. No expectant management arm of study included. Also women were excluded if tocolysis failed and they delivered within 24 h of randomisation.

El‐Qarmalawi 1990

Assessed treatment with either prostaglandins or oxytocin for women with PPROM. In all women induction was commenced 3 h after PPROM. The study did not assess the intervention of early birth, rather the mode of induction of labour.

Fayez 1978

Quasi‐randomised trial
Allocation to treatment groups by odd or even hospital record number

Gloeb 1989

Included women from 34‐41 completed weeks' gestation
Unable to extract subgroup of women prior to term

Griffith‐Jones 1990

Unable to establish that all women were prior to term
Included women greater than 35 weeks' gestation

Haghighi 2006

Assessed intravaginal misoprostol for induction of labour in women with PPROM for pregnancy termination

Lacaze 2006

This study was terminated prematurely due to slow recruitment.

Ladfors 1996

Unable to establish that all women were prior to 37 weeks.
Study included women from 34‐42 weeks

Makhlouf 1997

Abstract available only
Randomisation schema not available in abstract. Abstract did not quantify events in either early birth or expectant management groups

Mateos 1998

Included women at term and prior to term. Included women greater than 34 weeks' gestation but subgroup analysis of women prior to term not able to be performed

Miodovnik 1988

Did not assess intervention of early birth

Parsons 1989

Abstract only
Not enough information to assess methodology for inclusion or obtain meaningful results States trial was prospective but it does not appear to have been a randomised trial

Perez 1992

Did not include a group of women with expectant management. Women with PPROM were randomised to either induction with prostaglandin or induction with oxytocin within 12 h of presenting to hospital with PPROM

Van Heerden 1996

Included women prior to term and at term
Unable to extract data on subgroup of women who were prior to term

PPROM: preterm prelabour rupture of the membranes
RCT: randomised controlled trial

Characteristics of ongoing studies [ordered by study ID]

Pasquier 2006

Trial name or title

The MICADO study

Methods

A RCT in 23 hospitals to compare intentional birth with expectant management in women with preterm premature rupture of the membranes.

Participants

Women with preterm prelabour rupture of the membranes between 28 and 31 weeks' gestation.

Randomised to intervention or control 24 h after the second dose of corticosteroids

Interventions

Early birth

Outcomes

Starting date

2006

Contact information

Jean Charles Pasquier, Department of Obstetrics and Gynecology, Hospital Herriot, Lyon, France.

Notes

Data and analyses

Open in table viewer
Comparison 1. Any planned birth versus expectant management: by type

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection/sepsis Show forest plot

12

3628

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.66, 1.30]

Analysis 1.1

Comparison 1 Any planned birth versus expectant management: by type, Outcome 1 Neonatal infection/sepsis.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 1 Neonatal infection/sepsis.

2 Neonatal infection confirmed with positive blood culture Show forest plot

7

2925

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.70, 2.21]

Analysis 1.2

Comparison 1 Any planned birth versus expectant management: by type, Outcome 2 Neonatal infection confirmed with positive blood culture.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 2 Neonatal infection confirmed with positive blood culture.

3 Respiratory distress syndrome Show forest plot

12

3622

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.05, 1.53]

Analysis 1.3

Comparison 1 Any planned birth versus expectant management: by type, Outcome 3 Respiratory distress syndrome.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 3 Respiratory distress syndrome.

4 Caesarean section Show forest plot

12

3620

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.11, 1.44]

Analysis 1.4

Comparison 1 Any planned birth versus expectant management: by type, Outcome 4 Caesarean section.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 4 Caesarean section.

5 Perinatal mortality Show forest plot

11

3319

Risk Ratio (M‐H, Fixed, 95% CI)

1.76 [0.89, 3.50]

Analysis 1.5

Comparison 1 Any planned birth versus expectant management: by type, Outcome 5 Perinatal mortality.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 5 Perinatal mortality.

6 Intrauterine death Show forest plot

11

3321

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.13, 1.55]

Analysis 1.6

Comparison 1 Any planned birth versus expectant management: by type, Outcome 6 Intrauterine death.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 6 Intrauterine death.

7 Cord prolapse Show forest plot

4

2722

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.33, 4.61]

Analysis 1.7

Comparison 1 Any planned birth versus expectant management: by type, Outcome 7 Cord prolapse.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 7 Cord prolapse.

8 Gestational age at birth (weeks) Show forest plot

8

3139

Mean Difference (IV, Fixed, 95% CI)

‐0.48 [‐0.57, ‐0.39]

Analysis 1.8

Comparison 1 Any planned birth versus expectant management: by type, Outcome 8 Gestational age at birth (weeks).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 8 Gestational age at birth (weeks).

9 Neonatal death Show forest plot

11

3316

Risk Ratio (M‐H, Fixed, 95% CI)

2.55 [1.17, 5.56]

Analysis 1.9

Comparison 1 Any planned birth versus expectant management: by type, Outcome 9 Neonatal death.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 9 Neonatal death.

10 Suspected neonatal infection Show forest plot

3

829

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.36, 0.88]

Analysis 1.10

Comparison 1 Any planned birth versus expectant management: by type, Outcome 10 Suspected neonatal infection.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 10 Suspected neonatal infection.

11 Neonatal treatment with antibiotics Show forest plot

4

2638

Risk Ratio (M‐H, Random, 95% CI)

0.86 [0.63, 1.19]

Analysis 1.11

Comparison 1 Any planned birth versus expectant management: by type, Outcome 11 Neonatal treatment with antibiotics.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 11 Neonatal treatment with antibiotics.

12 Need for ventilation Show forest plot

7

2895

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [1.02, 1.58]

Analysis 1.12

Comparison 1 Any planned birth versus expectant management: by type, Outcome 12 Need for ventilation.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 12 Need for ventilation.

13 Duration of oxygen therapy (days) Show forest plot

1

73

Mean Difference (IV, Fixed, 95% CI)

‐3.05 [‐6.92, 0.82]

Analysis 1.13

Comparison 1 Any planned birth versus expectant management: by type, Outcome 13 Duration of oxygen therapy (days).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 13 Duration of oxygen therapy (days).

14 Umbilical cord arterial pH Show forest plot

1

120

Mean Difference (IV, Fixed, 95% CI)

0.09 [0.07, 0.11]

Analysis 1.14

Comparison 1 Any planned birth versus expectant management: by type, Outcome 14 Umbilical cord arterial pH.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 14 Umbilical cord arterial pH.

15 Birthweight (g) Show forest plot

10

3263

Mean Difference (IV, Random, 95% CI)

‐47.10 [‐96.00, 1.80]

Analysis 1.15

Comparison 1 Any planned birth versus expectant management: by type, Outcome 15 Birthweight (g).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 15 Birthweight (g).

16 Apgar score less than 7 at 5 minutes Show forest plot

5

2700

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.54, 1.69]

Analysis 1.16

Comparison 1 Any planned birth versus expectant management: by type, Outcome 16 Apgar score less than 7 at 5 minutes.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 16 Apgar score less than 7 at 5 minutes.

17 Abnormality on cerebral ultrasound Show forest plot

3

271

Risk Ratio (M‐H, Fixed, 95% CI)

1.90 [0.52, 6.92]

Analysis 1.17

Comparison 1 Any planned birth versus expectant management: by type, Outcome 17 Abnormality on cerebral ultrasound.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 17 Abnormality on cerebral ultrasound.

18 Periventricular leukomalacia Show forest plot

2

707

Risk Ratio (M‐H, Fixed, 95% CI)

1.00 [0.14, 6.99]

Analysis 1.18

Comparison 1 Any planned birth versus expectant management: by type, Outcome 18 Periventricular leukomalacia.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 18 Periventricular leukomalacia.

19 Cerebroventricular haemorrhage Show forest plot

6

1095

Risk Ratio (M‐H, Fixed, 95% CI)

1.19 [0.40, 3.52]

Analysis 1.19

Comparison 1 Any planned birth versus expectant management: by type, Outcome 19 Cerebroventricular haemorrhage.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 19 Cerebroventricular haemorrhage.

20 Necrotising enterocolitis Show forest plot

6

2842

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.25, 2.62]

Analysis 1.20

Comparison 1 Any planned birth versus expectant management: by type, Outcome 20 Necrotising enterocolitis.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 20 Necrotising enterocolitis.

21 Severe respiratory distress Show forest plot

3

321

Risk Ratio (M‐H, Fixed, 95% CI)

1.54 [0.80, 2.97]

Analysis 1.21

Comparison 1 Any planned birth versus expectant management: by type, Outcome 21 Severe respiratory distress.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 21 Severe respiratory distress.

22 Admission to neonatal intensive care unit Show forest plot

4

2691

Risk Ratio (M‐H, Fixed, 95% CI)

1.16 [1.08, 1.24]

Analysis 1.22

Comparison 1 Any planned birth versus expectant management: by type, Outcome 22 Admission to neonatal intensive care unit.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 22 Admission to neonatal intensive care unit.

23 Length of stay in neonatal intensive care unit (days) Show forest plot

4

2121

Mean Difference (IV, Random, 95% CI)

‐0.17 [‐1.62, 1.27]

Analysis 1.23

Comparison 1 Any planned birth versus expectant management: by type, Outcome 23 Length of stay in neonatal intensive care unit (days).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 23 Length of stay in neonatal intensive care unit (days).

24 Duration (days) from birth to neonatal hospital discharge Show forest plot

6

2832

Mean Difference (IV, Random, 95% CI)

0.67 [‐0.28, 1.61]

Analysis 1.24

Comparison 1 Any planned birth versus expectant management: by type, Outcome 24 Duration (days) from birth to neonatal hospital discharge.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 24 Duration (days) from birth to neonatal hospital discharge.

25 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Random, 95% CI)

0.50 [0.26, 0.95]

Analysis 1.25

Comparison 1 Any planned birth versus expectant management: by type, Outcome 25 Chorioamnionitis.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 25 Chorioamnionitis.

26 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

Analysis 1.26

Comparison 1 Any planned birth versus expectant management: by type, Outcome 26 Endometritis.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 26 Endometritis.

27 Postpartum fever Show forest plot

1

1835

Risk Ratio (M‐H, Fixed, 95% CI)

0.52 [0.26, 1.03]

Analysis 1.27

Comparison 1 Any planned birth versus expectant management: by type, Outcome 27 Postpartum fever.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 27 Postpartum fever.

28 Placental abruption Show forest plot

1

1835

Risk Ratio (M‐H, Fixed, 95% CI)

1.19 [0.36, 3.87]

Analysis 1.28

Comparison 1 Any planned birth versus expectant management: by type, Outcome 28 Placental abruption.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 28 Placental abruption.

29 Induction of labour Show forest plot

4

2691

Risk Ratio (M‐H, Fixed, 95% CI)

2.18 [2.01, 2.36]

Analysis 1.29

Comparison 1 Any planned birth versus expectant management: by type, Outcome 29 Induction of labour.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 29 Induction of labour.

30 Use of epidural/spinal anaesthesia Show forest plot

3

2562

Risk Ratio (M‐H, Random, 95% CI)

1.28 [0.99, 1.65]

Analysis 1.30

Comparison 1 Any planned birth versus expectant management: by type, Outcome 30 Use of epidural/spinal anaesthesia.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 30 Use of epidural/spinal anaesthesia.

31 Vaginal birth Show forest plot

12

3618

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.91, 0.97]

Analysis 1.31

Comparison 1 Any planned birth versus expectant management: by type, Outcome 31 Vaginal birth.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 31 Vaginal birth.

32 Operative vaginal birth Show forest plot

4

2685

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.67, 1.10]

Analysis 1.32

Comparison 1 Any planned birth versus expectant management: by type, Outcome 32 Operative vaginal birth.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 32 Operative vaginal birth.

33 Caesarean section for fetal distress Show forest plot

7

2918

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.66, 1.20]

Analysis 1.33

Comparison 1 Any planned birth versus expectant management: by type, Outcome 33 Caesarean section for fetal distress.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 33 Caesarean section for fetal distress.

34 Duration (days) of maternal hospitalisation Show forest plot

6

2848

Mean Difference (IV, Random, 95% CI)

‐1.75 [‐2.45, ‐1.05]

Analysis 1.34

Comparison 1 Any planned birth versus expectant management: by type, Outcome 34 Duration (days) of maternal hospitalisation.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 34 Duration (days) of maternal hospitalisation.

35 Duration (days) of antenatal hospitalisation Show forest plot

1

73

Mean Difference (IV, Fixed, 95% CI)

‐6.30 [‐9.67, ‐2.93]

Analysis 1.35

Comparison 1 Any planned birth versus expectant management: by type, Outcome 35 Duration (days) of antenatal hospitalisation.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 35 Duration (days) of antenatal hospitalisation.

36 Duration (days) of maternal hospitalisation (excluding trials with antenatal discharge) Show forest plot

2

213

Mean Difference (IV, Random, 95% CI)

‐1.64 [‐3.06, ‐0.23]

Analysis 1.36

Comparison 1 Any planned birth versus expectant management: by type, Outcome 36 Duration (days) of maternal hospitalisation (excluding trials with antenatal discharge).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 36 Duration (days) of maternal hospitalisation (excluding trials with antenatal discharge).

37 Time (hours) from randomisation to birth Show forest plot

3

2571

Mean Difference (IV, Fixed, 95% CI)

‐79.48 [‐88.27, ‐70.69]

Analysis 1.37

Comparison 1 Any planned birth versus expectant management: by type, Outcome 37 Time (hours) from randomisation to birth.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 37 Time (hours) from randomisation to birth.

38 Disability at 2 years, abnormal CBCL Show forest plot

1

199

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.26, 1.59]

Analysis 1.38

Comparison 1 Any planned birth versus expectant management: by type, Outcome 38 Disability at 2 years, abnormal CBCL.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 38 Disability at 2 years, abnormal CBCL.

39 Disability at 2 years, abnormal ASQ Show forest plot

1

228

Risk Ratio (M‐H, Fixed, 95% CI)

0.61 [0.35, 1.05]

Analysis 1.39

Comparison 1 Any planned birth versus expectant management: by type, Outcome 39 Disability at 2 years, abnormal ASQ.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 39 Disability at 2 years, abnormal ASQ.

40 Maternal satisfaction Show forest plot

1

493

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.86, 1.13]

Analysis 1.40

Comparison 1 Any planned birth versus expectant management: by type, Outcome 40 Maternal satisfaction.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 40 Maternal satisfaction.

41 Breastfeeding > 12 weeks Show forest plot

1

415

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.80, 1.12]

Analysis 1.41

Comparison 1 Any planned birth versus expectant management: by type, Outcome 41 Breastfeeding > 12 weeks.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 41 Breastfeeding > 12 weeks.

Open in table viewer
Comparison 2. Any planned birth versus expectant management (subgroup analysis by corticosteroid usage)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection Show forest plot

12

3652

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.68, 1.32]

Analysis 2.1

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 1 Neonatal infection.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 1 Neonatal infection.

1.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 No antenatal corticosteroids

6

495

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.48, 2.03]

1.3 Some antenatal corticosteroids

6

2850

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.64, 1.41]

1.4 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.80 [0.25, 2.55]

2 Neonatal infection confirmed with positive culture Show forest plot

7

2939

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [0.74, 2.23]

Analysis 2.2

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 2 Neonatal infection confirmed with positive culture.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 2 Neonatal infection confirmed with positive culture.

2.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 No antenatal corticosteroids

3

259

Risk Ratio (M‐H, Fixed, 95% CI)

0.60 [0.18, 2.04]

2.3 Some antenatal corticosteroids

5

2680

Risk Ratio (M‐H, Fixed, 95% CI)

1.59 [0.85, 3.00]

3 Respiratory distress syndrome Show forest plot

12

3646

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [1.07, 1.56]

Analysis 2.3

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 3 Respiratory distress syndrome.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 3 Respiratory distress syndrome.

3.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 No antenatal corticosteroids

6

495

Risk Ratio (M‐H, Fixed, 95% CI)

1.32 [0.96, 1.83]

3.3 Some antenatal corticosteroids

6

2844

Risk Ratio (M‐H, Fixed, 95% CI)

1.28 [1.01, 1.63]

3.4 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.55, 2.94]

4 Caesarean section Show forest plot

12

3644

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.11, 1.44]

Analysis 2.4

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 4 Caesarean section.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 4 Caesarean section.

4.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 No antenatal corticosteroids

6

493

Risk Ratio (M‐H, Fixed, 95% CI)

1.43 [1.00, 2.06]

4.3 Some antenatal corticosteroids

6

2844

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [1.10, 1.47]

4.4 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.51, 1.61]

5 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Fixed, 95% CI)

0.49 [0.33, 0.72]

Analysis 2.5

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 5 Chorioamnionitis.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 5 Chorioamnionitis.

5.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 No antenatal corticosteroids

4

398

Risk Ratio (M‐H, Fixed, 95% CI)

0.38 [0.22, 0.67]

5.3 Some antenatal corticosteroids

4

960

Risk Ratio (M‐H, Fixed, 95% CI)

0.61 [0.36, 1.06]

6 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

Analysis 2.6

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 6 Endometritis.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 6 Endometritis.

6.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 No antenatal corticosteroids

2

185

Risk Ratio (M‐H, Fixed, 95% CI)

1.38 [0.32, 5.94]

6.3 Some antenatal corticosteroids

5

2795

Risk Ratio (M‐H, Fixed, 95% CI)

1.64 [0.99, 2.72]

Open in table viewer
Comparison 3. Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection Show forest plot

12

3628

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.66, 1.30]

Analysis 3.1

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 1 Neonatal infection.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 1 Neonatal infection.

1.1 Greater than 34 weeks' gestation

5

2998

Risk Ratio (M‐H, Fixed, 95% CI)

0.71 [0.47, 1.07]

1.2 Less than 34 weeks' gestation

5

490

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [0.74, 3.50]

1.3 Not specified (wider span)

2

140

Risk Ratio (M‐H, Fixed, 95% CI)

2.00 [0.65, 6.18]

2 Neonatal infection confirmed with positive culture Show forest plot

7

2925

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.70, 2.21]

Analysis 3.2

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 2 Neonatal infection confirmed with positive culture.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 2 Neonatal infection confirmed with positive culture.

2.1 Greater than 34 weeks' gestation

4

2691

Risk Ratio (M‐H, Fixed, 95% CI)

1.07 [0.52, 2.20]

2.2 Less than 34 weeks' gestation

2

141

Risk Ratio (M‐H, Fixed, 95% CI)

1.67 [0.52, 5.35]

2.3 Not specified (wider span)

1

93

Risk Ratio (M‐H, Fixed, 95% CI)

1.53 [0.27, 8.75]

3 Respiratory distress syndrome Show forest plot

12

3622

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.05, 1.53]

Analysis 3.3

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 3 Respiratory distress syndrome.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 3 Respiratory distress syndrome.

3.1 Greater than 34 weeks' gestation

5

2992

Risk Ratio (M‐H, Fixed, 95% CI)

1.45 [1.10, 1.90]

3.2 Less than 34 weeks' gestation

5

490

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.84, 1.43]

3.3 Not specified (wider span)

2

140

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.27, 2.42]

4 Caesarean section Show forest plot

12

3620

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.11, 1.44]

Analysis 3.4

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 4 Caesarean section.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 4 Caesarean section.

4.1 Greater than 34 weeks' gestation

5

2992

Risk Ratio (M‐H, Fixed, 95% CI)

1.22 [1.05, 1.42]

4.2 Less than 34 weeks' gestation

5

488

Risk Ratio (M‐H, Fixed, 95% CI)

1.46 [1.08, 1.96]

4.3 Not specified (wider span)

2

140

Risk Ratio (M‐H, Fixed, 95% CI)

1.21 [0.45, 3.28]

5 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Fixed, 95% CI)

0.49 [0.33, 0.72]

Analysis 3.5

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 5 Chorioamnionitis.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 5 Chorioamnionitis.

5.1 Greater than 34 weeks' gestation

3

847

Risk Ratio (M‐H, Fixed, 95% CI)

0.26 [0.12, 0.57]

5.2 Less than 34 weeks' gestation

4

418

Risk Ratio (M‐H, Fixed, 95% CI)

0.77 [0.45, 1.30]

5.3 Not specified (wider span)

1

93

Risk Ratio (M‐H, Fixed, 95% CI)

0.39 [0.15, 1.01]

6 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

Analysis 3.6

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 6 Endometritis.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 6 Endometritis.

6.1 Greater than 34 weeks' gestation

3

2562

Risk Ratio (M‐H, Fixed, 95% CI)

0.37 [0.10, 1.40]

6.2 Less than 34 weeks' gestation

4

418

Risk Ratio (M‐H, Fixed, 95% CI)

2.23 [1.29, 3.84]

Open in table viewer
Comparison 4. Any planned birth versus expectant management (subgroup analysis by antibiotic use)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection Show forest plot

12

3625

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.66, 1.30]

Analysis 4.1

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 1 Neonatal infection.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 1 Neonatal infection.

1.1 Prophylactic antibiotics used

2

1702

Risk Ratio (M‐H, Fixed, 95% CI)

0.74 [0.42, 1.31]

1.2 Prophylactic antibiotics not used

8

880

Risk Ratio (M‐H, Fixed, 95% CI)

1.42 [0.81, 2.51]

1.3 Some prophylactic antibiotics used

2

736

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.30, 1.46]

1.4 Not specified

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.80 [0.25, 2.55]

2 Neonatal infection confirmed with positive culture Show forest plot

7

2925

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.70, 2.21]

Analysis 4.2

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 2 Neonatal infection confirmed with positive culture.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 2 Neonatal infection confirmed with positive culture.

2.1 Prophylactic antibiotics used

1

120

Risk Ratio (M‐H, Fixed, 95% CI)

0.16 [0.01, 2.99]

2.2 Prophylactic antibiotics not used

3

234

Risk Ratio (M‐H, Fixed, 95% CI)

1.63 [0.62, 4.28]

2.3 Some prophylactic antibiotics used

3

2571

Risk Ratio (M‐H, Fixed, 95% CI)

1.35 [0.62, 2.93]

3 Respiratory distress syndrome Show forest plot

12

3622

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [1.06, 1.56]

Analysis 4.3

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 3 Respiratory distress syndrome.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 3 Respiratory distress syndrome.

3.1 Prophylactic antibiotics used

1

120

Risk Ratio (M‐H, Fixed, 95% CI)

1.11 [0.23, 5.26]

3.2 Prophylactic antibiotics not used

7

630

Risk Ratio (M‐H, Fixed, 95% CI)

1.11 [0.85, 1.45]

3.3 Some prophylactic antibiotics used

3

2565

Risk Ratio (M‐H, Fixed, 95% CI)

1.48 [1.10, 1.99]

3.4 Not specified

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.55, 2.94]

4 Caesarean section Show forest plot

12

3620

Risk Ratio (M‐H, Fixed, 95% CI)

1.30 [1.14, 1.49]

Analysis 4.4

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 4 Caesarean section.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 4 Caesarean section.

4.1 Prophylactic antibiotics used

1

120

Risk Ratio (M‐H, Fixed, 95% CI)

1.47 [0.34, 6.30]

4.2 Prophylactic antibiotics not used

7

628

Risk Ratio (M‐H, Fixed, 95% CI)

1.43 [1.08, 1.90]

4.3 Some prophylactic antibiotics used

3

2565

Risk Ratio (M‐H, Fixed, 95% CI)

1.31 [1.12, 1.53]

4.4 Not specified

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.51, 1.61]

5 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Random, 95% CI)

0.50 [0.26, 0.95]

Analysis 4.5

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 5 Chorioamnionitis.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 5 Chorioamnionitis.

5.1 Prophylactic antibiotics used

1

120

Risk Ratio (M‐H, Random, 95% CI)

0.11 [0.01, 0.84]

5.2 Prophylactic antibiotics not used

5

511

Risk Ratio (M‐H, Random, 95% CI)

0.69 [0.34, 1.41]

5.3 Some prophylactic antibiotics used

2

727

Risk Ratio (M‐H, Random, 95% CI)

0.35 [0.15, 0.86]

6 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

Analysis 4.6

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 6 Endometritis.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 6 Endometritis.

6.1 Prophylactic antibiotics used

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Prophylactic antibiotics not used

4

418

Risk Ratio (M‐H, Fixed, 95% CI)

2.23 [1.29, 3.84]

6.3 Some prophylactic antibiotics used

3

2562

Risk Ratio (M‐H, Fixed, 95% CI)

0.37 [0.10, 1.40]

Open in table viewer
Comparison 5. Any planned birth versus expectant management (subgroup analysis by timing of early delivery)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection Show forest plot

12

3628

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.66, 1.30]

Analysis 5.1

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 1 Neonatal infection.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 1 Neonatal infection.

1.1 Less than 24 hours from randomisation

4

391

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.41, 1.99]

1.2 Greater than 24 hours from randomisation

7

2930

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.64, 1.41]

1.3 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.80 [0.25, 2.55]

2 Neonatal infection confirmed with positive culture Show forest plot

7

2925

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.70, 2.21]

Analysis 5.2

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 2 Neonatal infection confirmed with positive culture.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 2 Neonatal infection confirmed with positive culture.

2.1 Less than 24 hours from randomisation

2

213

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.18, 2.53]

2.2 Greater than 24 hours from randomisation

5

2712

Risk Ratio (M‐H, Fixed, 95% CI)

1.44 [0.76, 2.75]

3 Respiratory distress syndrome Show forest plot

12

3622

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [1.06, 1.56]

Analysis 5.3

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 3 Respiratory distress syndrome.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 3 Respiratory distress syndrome.

3.1 Less than 24 hours from randomisation

4

391

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.65, 1.50]

3.2 Greater than 24 hours from randomisation

7

2924

Risk Ratio (M‐H, Fixed, 95% CI)

1.37 [1.10, 1.71]

3.3 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.55, 2.94]

4 Caesarean section Show forest plot

12

3620

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.11, 1.44]

Analysis 5.4

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 4 Caesarean section.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 4 Caesarean section.

4.1 Less than 24 hours from randomisation

4

389

Risk Ratio (M‐H, Fixed, 95% CI)

1.59 [0.90, 2.81]

4.2 Greater than 24 hours from randomisation

7

2924

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [1.10, 1.46]

4.3 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.51, 1.61]

5 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Random, 95% CI)

0.50 [0.26, 0.95]

Analysis 5.5

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 5 Chorioamnionitis.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 5 Chorioamnionitis.

5.1 Less than 24 hours from randomisation

3

342

Risk Ratio (M‐H, Random, 95% CI)

0.25 [0.10, 0.61]

5.2 Greater than 24 hours from randomisation

5

1016

Risk Ratio (M‐H, Random, 95% CI)

0.76 [0.41, 1.42]

6 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

Analysis 5.6

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 6 Endometritis.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 6 Endometritis.

6.1 Less than 24 hours from randomisation

1

129

Risk Ratio (M‐H, Fixed, 95% CI)

1.67 [0.29, 9.68]

6.2 Greater than 24 hours from randomisation

6

2851

Risk Ratio (M‐H, Fixed, 95% CI)

1.60 [0.98, 2.63]

Study flow diagram
Figures and Tables -
Figure 1

Study flow diagram

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies
Figures and Tables -
Figure 2

Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies

Risk of bias summary: review authors' judgements about each risk of bias item for each included study
Figures and Tables -
Figure 3

Risk of bias summary: review authors' judgements about each risk of bias item for each included study

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.1 Neonatal infection/sepsis
Figures and Tables -
Figure 4

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.1 Neonatal infection/sepsis

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.3 Respiratory distress syndrome
Figures and Tables -
Figure 5

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.3 Respiratory distress syndrome

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.4 Caesarean section
Figures and Tables -
Figure 6

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.4 Caesarean section

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.5 Perinatal mortality
Figures and Tables -
Figure 7

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.5 Perinatal mortality

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.6 Intrauterine death
Figures and Tables -
Figure 8

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.6 Intrauterine death

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.9 Neonatal death
Figures and Tables -
Figure 9

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.9 Neonatal death

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.15 Birthweight (g)
Figures and Tables -
Figure 10

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.15 Birthweight (g)

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.31 Vaginal birth
Figures and Tables -
Figure 11

Funnel plot of comparison: 1 Any planned birth versus expectant management: by type, outcome: 1.31 Vaginal birth

Comparison 1 Any planned birth versus expectant management: by type, Outcome 1 Neonatal infection/sepsis.
Figures and Tables -
Analysis 1.1

Comparison 1 Any planned birth versus expectant management: by type, Outcome 1 Neonatal infection/sepsis.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 2 Neonatal infection confirmed with positive blood culture.
Figures and Tables -
Analysis 1.2

Comparison 1 Any planned birth versus expectant management: by type, Outcome 2 Neonatal infection confirmed with positive blood culture.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 3 Respiratory distress syndrome.
Figures and Tables -
Analysis 1.3

Comparison 1 Any planned birth versus expectant management: by type, Outcome 3 Respiratory distress syndrome.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 4 Caesarean section.
Figures and Tables -
Analysis 1.4

Comparison 1 Any planned birth versus expectant management: by type, Outcome 4 Caesarean section.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 5 Perinatal mortality.
Figures and Tables -
Analysis 1.5

Comparison 1 Any planned birth versus expectant management: by type, Outcome 5 Perinatal mortality.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 6 Intrauterine death.
Figures and Tables -
Analysis 1.6

Comparison 1 Any planned birth versus expectant management: by type, Outcome 6 Intrauterine death.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 7 Cord prolapse.
Figures and Tables -
Analysis 1.7

Comparison 1 Any planned birth versus expectant management: by type, Outcome 7 Cord prolapse.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 8 Gestational age at birth (weeks).
Figures and Tables -
Analysis 1.8

Comparison 1 Any planned birth versus expectant management: by type, Outcome 8 Gestational age at birth (weeks).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 9 Neonatal death.
Figures and Tables -
Analysis 1.9

Comparison 1 Any planned birth versus expectant management: by type, Outcome 9 Neonatal death.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 10 Suspected neonatal infection.
Figures and Tables -
Analysis 1.10

Comparison 1 Any planned birth versus expectant management: by type, Outcome 10 Suspected neonatal infection.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 11 Neonatal treatment with antibiotics.
Figures and Tables -
Analysis 1.11

Comparison 1 Any planned birth versus expectant management: by type, Outcome 11 Neonatal treatment with antibiotics.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 12 Need for ventilation.
Figures and Tables -
Analysis 1.12

Comparison 1 Any planned birth versus expectant management: by type, Outcome 12 Need for ventilation.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 13 Duration of oxygen therapy (days).
Figures and Tables -
Analysis 1.13

Comparison 1 Any planned birth versus expectant management: by type, Outcome 13 Duration of oxygen therapy (days).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 14 Umbilical cord arterial pH.
Figures and Tables -
Analysis 1.14

Comparison 1 Any planned birth versus expectant management: by type, Outcome 14 Umbilical cord arterial pH.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 15 Birthweight (g).
Figures and Tables -
Analysis 1.15

Comparison 1 Any planned birth versus expectant management: by type, Outcome 15 Birthweight (g).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 16 Apgar score less than 7 at 5 minutes.
Figures and Tables -
Analysis 1.16

Comparison 1 Any planned birth versus expectant management: by type, Outcome 16 Apgar score less than 7 at 5 minutes.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 17 Abnormality on cerebral ultrasound.
Figures and Tables -
Analysis 1.17

Comparison 1 Any planned birth versus expectant management: by type, Outcome 17 Abnormality on cerebral ultrasound.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 18 Periventricular leukomalacia.
Figures and Tables -
Analysis 1.18

Comparison 1 Any planned birth versus expectant management: by type, Outcome 18 Periventricular leukomalacia.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 19 Cerebroventricular haemorrhage.
Figures and Tables -
Analysis 1.19

Comparison 1 Any planned birth versus expectant management: by type, Outcome 19 Cerebroventricular haemorrhage.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 20 Necrotising enterocolitis.
Figures and Tables -
Analysis 1.20

Comparison 1 Any planned birth versus expectant management: by type, Outcome 20 Necrotising enterocolitis.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 21 Severe respiratory distress.
Figures and Tables -
Analysis 1.21

Comparison 1 Any planned birth versus expectant management: by type, Outcome 21 Severe respiratory distress.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 22 Admission to neonatal intensive care unit.
Figures and Tables -
Analysis 1.22

Comparison 1 Any planned birth versus expectant management: by type, Outcome 22 Admission to neonatal intensive care unit.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 23 Length of stay in neonatal intensive care unit (days).
Figures and Tables -
Analysis 1.23

Comparison 1 Any planned birth versus expectant management: by type, Outcome 23 Length of stay in neonatal intensive care unit (days).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 24 Duration (days) from birth to neonatal hospital discharge.
Figures and Tables -
Analysis 1.24

Comparison 1 Any planned birth versus expectant management: by type, Outcome 24 Duration (days) from birth to neonatal hospital discharge.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 25 Chorioamnionitis.
Figures and Tables -
Analysis 1.25

Comparison 1 Any planned birth versus expectant management: by type, Outcome 25 Chorioamnionitis.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 26 Endometritis.
Figures and Tables -
Analysis 1.26

Comparison 1 Any planned birth versus expectant management: by type, Outcome 26 Endometritis.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 27 Postpartum fever.
Figures and Tables -
Analysis 1.27

Comparison 1 Any planned birth versus expectant management: by type, Outcome 27 Postpartum fever.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 28 Placental abruption.
Figures and Tables -
Analysis 1.28

Comparison 1 Any planned birth versus expectant management: by type, Outcome 28 Placental abruption.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 29 Induction of labour.
Figures and Tables -
Analysis 1.29

Comparison 1 Any planned birth versus expectant management: by type, Outcome 29 Induction of labour.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 30 Use of epidural/spinal anaesthesia.
Figures and Tables -
Analysis 1.30

Comparison 1 Any planned birth versus expectant management: by type, Outcome 30 Use of epidural/spinal anaesthesia.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 31 Vaginal birth.
Figures and Tables -
Analysis 1.31

Comparison 1 Any planned birth versus expectant management: by type, Outcome 31 Vaginal birth.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 32 Operative vaginal birth.
Figures and Tables -
Analysis 1.32

Comparison 1 Any planned birth versus expectant management: by type, Outcome 32 Operative vaginal birth.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 33 Caesarean section for fetal distress.
Figures and Tables -
Analysis 1.33

Comparison 1 Any planned birth versus expectant management: by type, Outcome 33 Caesarean section for fetal distress.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 34 Duration (days) of maternal hospitalisation.
Figures and Tables -
Analysis 1.34

Comparison 1 Any planned birth versus expectant management: by type, Outcome 34 Duration (days) of maternal hospitalisation.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 35 Duration (days) of antenatal hospitalisation.
Figures and Tables -
Analysis 1.35

Comparison 1 Any planned birth versus expectant management: by type, Outcome 35 Duration (days) of antenatal hospitalisation.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 36 Duration (days) of maternal hospitalisation (excluding trials with antenatal discharge).
Figures and Tables -
Analysis 1.36

Comparison 1 Any planned birth versus expectant management: by type, Outcome 36 Duration (days) of maternal hospitalisation (excluding trials with antenatal discharge).

Comparison 1 Any planned birth versus expectant management: by type, Outcome 37 Time (hours) from randomisation to birth.
Figures and Tables -
Analysis 1.37

Comparison 1 Any planned birth versus expectant management: by type, Outcome 37 Time (hours) from randomisation to birth.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 38 Disability at 2 years, abnormal CBCL.
Figures and Tables -
Analysis 1.38

Comparison 1 Any planned birth versus expectant management: by type, Outcome 38 Disability at 2 years, abnormal CBCL.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 39 Disability at 2 years, abnormal ASQ.
Figures and Tables -
Analysis 1.39

Comparison 1 Any planned birth versus expectant management: by type, Outcome 39 Disability at 2 years, abnormal ASQ.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 40 Maternal satisfaction.
Figures and Tables -
Analysis 1.40

Comparison 1 Any planned birth versus expectant management: by type, Outcome 40 Maternal satisfaction.

Comparison 1 Any planned birth versus expectant management: by type, Outcome 41 Breastfeeding > 12 weeks.
Figures and Tables -
Analysis 1.41

Comparison 1 Any planned birth versus expectant management: by type, Outcome 41 Breastfeeding > 12 weeks.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 1 Neonatal infection.
Figures and Tables -
Analysis 2.1

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 1 Neonatal infection.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 2 Neonatal infection confirmed with positive culture.
Figures and Tables -
Analysis 2.2

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 2 Neonatal infection confirmed with positive culture.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 3 Respiratory distress syndrome.
Figures and Tables -
Analysis 2.3

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 3 Respiratory distress syndrome.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 4 Caesarean section.
Figures and Tables -
Analysis 2.4

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 4 Caesarean section.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 5 Chorioamnionitis.
Figures and Tables -
Analysis 2.5

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 5 Chorioamnionitis.

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 6 Endometritis.
Figures and Tables -
Analysis 2.6

Comparison 2 Any planned birth versus expectant management (subgroup analysis by corticosteroid usage), Outcome 6 Endometritis.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 1 Neonatal infection.
Figures and Tables -
Analysis 3.1

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 1 Neonatal infection.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 2 Neonatal infection confirmed with positive culture.
Figures and Tables -
Analysis 3.2

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 2 Neonatal infection confirmed with positive culture.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 3 Respiratory distress syndrome.
Figures and Tables -
Analysis 3.3

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 3 Respiratory distress syndrome.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 4 Caesarean section.
Figures and Tables -
Analysis 3.4

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 4 Caesarean section.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 5 Chorioamnionitis.
Figures and Tables -
Analysis 3.5

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 5 Chorioamnionitis.

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 6 Endometritis.
Figures and Tables -
Analysis 3.6

Comparison 3 Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial), Outcome 6 Endometritis.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 1 Neonatal infection.
Figures and Tables -
Analysis 4.1

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 1 Neonatal infection.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 2 Neonatal infection confirmed with positive culture.
Figures and Tables -
Analysis 4.2

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 2 Neonatal infection confirmed with positive culture.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 3 Respiratory distress syndrome.
Figures and Tables -
Analysis 4.3

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 3 Respiratory distress syndrome.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 4 Caesarean section.
Figures and Tables -
Analysis 4.4

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 4 Caesarean section.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 5 Chorioamnionitis.
Figures and Tables -
Analysis 4.5

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 5 Chorioamnionitis.

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 6 Endometritis.
Figures and Tables -
Analysis 4.6

Comparison 4 Any planned birth versus expectant management (subgroup analysis by antibiotic use), Outcome 6 Endometritis.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 1 Neonatal infection.
Figures and Tables -
Analysis 5.1

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 1 Neonatal infection.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 2 Neonatal infection confirmed with positive culture.
Figures and Tables -
Analysis 5.2

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 2 Neonatal infection confirmed with positive culture.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 3 Respiratory distress syndrome.
Figures and Tables -
Analysis 5.3

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 3 Respiratory distress syndrome.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 4 Caesarean section.
Figures and Tables -
Analysis 5.4

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 4 Caesarean section.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 5 Chorioamnionitis.
Figures and Tables -
Analysis 5.5

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 5 Chorioamnionitis.

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 6 Endometritis.
Figures and Tables -
Analysis 5.6

Comparison 5 Any planned birth versus expectant management (subgroup analysis by timing of early delivery), Outcome 6 Endometritis.

Summary of findings for the main comparison. Planned early birth compared to expectant management for preterm prelabour rupture of membranes prior to 37 weeks' gestation

Planned early birth compared to expectant management for preterm prelabour rupture of membranes prior to 37 weeks' gestation

Patient or population: women with preterm prelabour rupture of membranes prior to 37 weeks' gestation
Settings: USA, the Netherlands, Mexico, Albania, Australia, New Zealand, Argentina, South Africa, Brazil, UK, Norway, Egypt, Uruguay, Poland, and Romania
Intervention: planned early birth
Comparison: expectant management

Outcomes

Illustrative comparative risks* (95% CI)

Relative effect
(95% CI)

No of participants
(studies)

Quality of the evidence
(GRADE)

Comments

Assumed risk

Corresponding risk

Expectant management

Planned early birth

Neonatal infection/sepsis
Follow‐up: 28 days

Study population

RR 0.93
(0.66 to 1.3)

3628
(12 studies)

⊕⊕⊕⊝
moderate1

37 per 1000

34 per 1000
(24 to 48)

Neonatal respiratory distress syndrome
Follow‐up: 28 days

Study population

RR 1.26
(1.05 to 1.53)

3622
(12 studies)

⊕⊕⊕⊕
high

84 per 1000

109 per 1000
(89 to 131)

Need for ventilation

Study population

RR 1.27
(1.02 to 1.58)

2895
(7 studies)

⊕⊕⊕⊕
high

86 per 1000

110 per 1000
(88 to 136)

Admission to neonatal intensive care
Follow‐up: 28 days

Study population

RR 1.16
(1.08 to 1.24)

2691
(4 studies)

⊕⊕⊕⊝
moderate1

428 per 1000

497 per 1000
(462 to 531)

Caesarean section

Study population

RR 1.26
(1.11 to 1.44)

3620
(12 studies)

⊕⊕⊕⊕
high

172 per 1000

217 per 1000
(191 to 248)

Chorioamnionitis

Study population

RR 0.50
(0.26 to 0.95)

1358
(8 studies)

⊕⊕⊕⊝
moderate2

103 per 1000

51 per 1000
(27 to 98)

Length of hospital stay (maternal)

The mean length of hospital stay (maternal) in the expectant group was
7.6 days

The mean length of hospital stay (maternal) in the early birth group was 1.75 days lower
(2.45 to 1.05 lower)

MD ‐1.75 (‐2.45 to ‐1.05)

2848
(6 studies)

⊕⊕⊕⊝
moderate3

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1Wide confidence interval crossing the line of no effect, and the lines of appreciable benefit and harm.
2Some statistical heterogeneity (I² = 48%).
3Statistical heterogeneity: I² = 63%, likely due to differences in women's management.

Figures and Tables -
Summary of findings for the main comparison. Planned early birth compared to expectant management for preterm prelabour rupture of membranes prior to 37 weeks' gestation
Table 1. Characteristics of trials assessing early birth with expectant management in women with PPROM

Trial

Sample size

Gestational age for inclusion (weeks)

Co‐interventions

Fetal lung maturity tested

Cox 1995

129

(131 babies)

61 ED

(62 babies)

68 EM

(69 babies)

30 to 34

  • No corticosteroids

  • No tocolysis

  • No prophylactic antibiotics

No

Eroiz‐Hernandez 1997

58

30 ED

28 EM

28 to 34

  • ED group given fetal lung maturity protocol of 6 doses of 250 mg of intravenous aminophylline every 8 hours

  • EM group managed with the same lung maturity protocol repeated weekly

  • No prophylactic antibiotics

  • Tocolysis if contracting

Yes, if positive excluded from randomisation

Garite 1981

160

80 ED

80 EM

28 to 34

  • Corticosteroids to ED group

  • Tocolysis to ED group if required

  • No prophylactic antibiotics

Yes: if L/S mature excluded from randomisation and delivered

Iams 1985

73

38 ED

35 EM

28 to 34

  • Corticosteroids to ED group

  • Tocolysis to ED group if required

  • No prophylactic antibiotics

Yes: if mature L/S excluded from randomisation and delivered

Koroveshi 2013

307

157 ED

150 EM

34 to 37

  • Not mentioned

No

Mercer 1993

93

46 ED

47 EM

32 to 36+ 6

  • No corticosteroids

  • No tocolysis

  • No prophylactic antibiotics

Yes: included if mature L/S

Morris 2016

1835

923 ED

912 EM

34 to 36+ 6

  • Antibiotics according to local protocol

  • Corticosteroids according to local protocol

  • Tocolysis according to local protocol

No

Naef 1998

120

57 ED

63 EM

34 to 36+ 6

  • No corticosteroids

  • No tocolysis

  • Prophylactic antibiotics for all women

No

Nelson 1985

68

22 ED and steroids

22 ED and no steroids

24 EM

28 to 34

  • Corticosteroids only to 1 of ED groups

  • Tocolysis to ED groups if required

  • No prophylactic antibiotics

No

Spinnato 1987

47

26 to ED

21 to EM

25 to 36

  • No corticosteroids

  • No tocolysis

  • No antibiotics

Yes: included if mature L/S

Van der Ham 2012a

532

(538 babies)

266 ED

(268 babies)

266 EM

(270 babies)

34 to 36+6

  • Antibiotics according to local protocol

  • Tocolysis dependent on local protocol

  • Corticosteroids given in PPROM < 34 weeks' gestational age

No

Van der Ham 2012b

195

(198 babies)

100 ED

(100 babies)

95 EM

(98 babies)

34 to 36+6

  • Antibiotics according to local protocol

  • Tocolysis dependent on local protocol

  • Corticosteroids given in PPROM < 34 weeks' gestational age

No

ED: early delivery
EM: expectant management
L/S: lecithin‐sphingomyelin

Figures and Tables -
Table 1. Characteristics of trials assessing early birth with expectant management in women with PPROM
Comparison 1. Any planned birth versus expectant management: by type

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection/sepsis Show forest plot

12

3628

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.66, 1.30]

2 Neonatal infection confirmed with positive blood culture Show forest plot

7

2925

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.70, 2.21]

3 Respiratory distress syndrome Show forest plot

12

3622

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.05, 1.53]

4 Caesarean section Show forest plot

12

3620

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.11, 1.44]

5 Perinatal mortality Show forest plot

11

3319

Risk Ratio (M‐H, Fixed, 95% CI)

1.76 [0.89, 3.50]

6 Intrauterine death Show forest plot

11

3321

Risk Ratio (M‐H, Fixed, 95% CI)

0.45 [0.13, 1.55]

7 Cord prolapse Show forest plot

4

2722

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.33, 4.61]

8 Gestational age at birth (weeks) Show forest plot

8

3139

Mean Difference (IV, Fixed, 95% CI)

‐0.48 [‐0.57, ‐0.39]

9 Neonatal death Show forest plot

11

3316

Risk Ratio (M‐H, Fixed, 95% CI)

2.55 [1.17, 5.56]

10 Suspected neonatal infection Show forest plot

3

829

Risk Ratio (M‐H, Fixed, 95% CI)

0.56 [0.36, 0.88]

11 Neonatal treatment with antibiotics Show forest plot

4

2638

Risk Ratio (M‐H, Random, 95% CI)

0.86 [0.63, 1.19]

12 Need for ventilation Show forest plot

7

2895

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [1.02, 1.58]

13 Duration of oxygen therapy (days) Show forest plot

1

73

Mean Difference (IV, Fixed, 95% CI)

‐3.05 [‐6.92, 0.82]

14 Umbilical cord arterial pH Show forest plot

1

120

Mean Difference (IV, Fixed, 95% CI)

0.09 [0.07, 0.11]

15 Birthweight (g) Show forest plot

10

3263

Mean Difference (IV, Random, 95% CI)

‐47.10 [‐96.00, 1.80]

16 Apgar score less than 7 at 5 minutes Show forest plot

5

2700

Risk Ratio (M‐H, Fixed, 95% CI)

0.96 [0.54, 1.69]

17 Abnormality on cerebral ultrasound Show forest plot

3

271

Risk Ratio (M‐H, Fixed, 95% CI)

1.90 [0.52, 6.92]

18 Periventricular leukomalacia Show forest plot

2

707

Risk Ratio (M‐H, Fixed, 95% CI)

1.00 [0.14, 6.99]

19 Cerebroventricular haemorrhage Show forest plot

6

1095

Risk Ratio (M‐H, Fixed, 95% CI)

1.19 [0.40, 3.52]

20 Necrotising enterocolitis Show forest plot

6

2842

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.25, 2.62]

21 Severe respiratory distress Show forest plot

3

321

Risk Ratio (M‐H, Fixed, 95% CI)

1.54 [0.80, 2.97]

22 Admission to neonatal intensive care unit Show forest plot

4

2691

Risk Ratio (M‐H, Fixed, 95% CI)

1.16 [1.08, 1.24]

23 Length of stay in neonatal intensive care unit (days) Show forest plot

4

2121

Mean Difference (IV, Random, 95% CI)

‐0.17 [‐1.62, 1.27]

24 Duration (days) from birth to neonatal hospital discharge Show forest plot

6

2832

Mean Difference (IV, Random, 95% CI)

0.67 [‐0.28, 1.61]

25 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Random, 95% CI)

0.50 [0.26, 0.95]

26 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

27 Postpartum fever Show forest plot

1

1835

Risk Ratio (M‐H, Fixed, 95% CI)

0.52 [0.26, 1.03]

28 Placental abruption Show forest plot

1

1835

Risk Ratio (M‐H, Fixed, 95% CI)

1.19 [0.36, 3.87]

29 Induction of labour Show forest plot

4

2691

Risk Ratio (M‐H, Fixed, 95% CI)

2.18 [2.01, 2.36]

30 Use of epidural/spinal anaesthesia Show forest plot

3

2562

Risk Ratio (M‐H, Random, 95% CI)

1.28 [0.99, 1.65]

31 Vaginal birth Show forest plot

12

3618

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.91, 0.97]

32 Operative vaginal birth Show forest plot

4

2685

Risk Ratio (M‐H, Fixed, 95% CI)

0.85 [0.67, 1.10]

33 Caesarean section for fetal distress Show forest plot

7

2918

Risk Ratio (M‐H, Fixed, 95% CI)

0.89 [0.66, 1.20]

34 Duration (days) of maternal hospitalisation Show forest plot

6

2848

Mean Difference (IV, Random, 95% CI)

‐1.75 [‐2.45, ‐1.05]

35 Duration (days) of antenatal hospitalisation Show forest plot

1

73

Mean Difference (IV, Fixed, 95% CI)

‐6.30 [‐9.67, ‐2.93]

36 Duration (days) of maternal hospitalisation (excluding trials with antenatal discharge) Show forest plot

2

213

Mean Difference (IV, Random, 95% CI)

‐1.64 [‐3.06, ‐0.23]

37 Time (hours) from randomisation to birth Show forest plot

3

2571

Mean Difference (IV, Fixed, 95% CI)

‐79.48 [‐88.27, ‐70.69]

38 Disability at 2 years, abnormal CBCL Show forest plot

1

199

Risk Ratio (M‐H, Fixed, 95% CI)

0.64 [0.26, 1.59]

39 Disability at 2 years, abnormal ASQ Show forest plot

1

228

Risk Ratio (M‐H, Fixed, 95% CI)

0.61 [0.35, 1.05]

40 Maternal satisfaction Show forest plot

1

493

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.86, 1.13]

41 Breastfeeding > 12 weeks Show forest plot

1

415

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.80, 1.12]

Figures and Tables -
Comparison 1. Any planned birth versus expectant management: by type
Comparison 2. Any planned birth versus expectant management (subgroup analysis by corticosteroid usage)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection Show forest plot

12

3652

Risk Ratio (M‐H, Fixed, 95% CI)

0.94 [0.68, 1.32]

1.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

1.2 No antenatal corticosteroids

6

495

Risk Ratio (M‐H, Fixed, 95% CI)

0.98 [0.48, 2.03]

1.3 Some antenatal corticosteroids

6

2850

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.64, 1.41]

1.4 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.80 [0.25, 2.55]

2 Neonatal infection confirmed with positive culture Show forest plot

7

2939

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [0.74, 2.23]

2.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

2.2 No antenatal corticosteroids

3

259

Risk Ratio (M‐H, Fixed, 95% CI)

0.60 [0.18, 2.04]

2.3 Some antenatal corticosteroids

5

2680

Risk Ratio (M‐H, Fixed, 95% CI)

1.59 [0.85, 3.00]

3 Respiratory distress syndrome Show forest plot

12

3646

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [1.07, 1.56]

3.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

3.2 No antenatal corticosteroids

6

495

Risk Ratio (M‐H, Fixed, 95% CI)

1.32 [0.96, 1.83]

3.3 Some antenatal corticosteroids

6

2844

Risk Ratio (M‐H, Fixed, 95% CI)

1.28 [1.01, 1.63]

3.4 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.55, 2.94]

4 Caesarean section Show forest plot

12

3644

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.11, 1.44]

4.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

4.2 No antenatal corticosteroids

6

493

Risk Ratio (M‐H, Fixed, 95% CI)

1.43 [1.00, 2.06]

4.3 Some antenatal corticosteroids

6

2844

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [1.10, 1.47]

4.4 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.51, 1.61]

5 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Fixed, 95% CI)

0.49 [0.33, 0.72]

5.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

5.2 No antenatal corticosteroids

4

398

Risk Ratio (M‐H, Fixed, 95% CI)

0.38 [0.22, 0.67]

5.3 Some antenatal corticosteroids

4

960

Risk Ratio (M‐H, Fixed, 95% CI)

0.61 [0.36, 1.06]

6 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

6.1 Antenatal corticosteroids

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 No antenatal corticosteroids

2

185

Risk Ratio (M‐H, Fixed, 95% CI)

1.38 [0.32, 5.94]

6.3 Some antenatal corticosteroids

5

2795

Risk Ratio (M‐H, Fixed, 95% CI)

1.64 [0.99, 2.72]

Figures and Tables -
Comparison 2. Any planned birth versus expectant management (subgroup analysis by corticosteroid usage)
Comparison 3. Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection Show forest plot

12

3628

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.66, 1.30]

1.1 Greater than 34 weeks' gestation

5

2998

Risk Ratio (M‐H, Fixed, 95% CI)

0.71 [0.47, 1.07]

1.2 Less than 34 weeks' gestation

5

490

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [0.74, 3.50]

1.3 Not specified (wider span)

2

140

Risk Ratio (M‐H, Fixed, 95% CI)

2.00 [0.65, 6.18]

2 Neonatal infection confirmed with positive culture Show forest plot

7

2925

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.70, 2.21]

2.1 Greater than 34 weeks' gestation

4

2691

Risk Ratio (M‐H, Fixed, 95% CI)

1.07 [0.52, 2.20]

2.2 Less than 34 weeks' gestation

2

141

Risk Ratio (M‐H, Fixed, 95% CI)

1.67 [0.52, 5.35]

2.3 Not specified (wider span)

1

93

Risk Ratio (M‐H, Fixed, 95% CI)

1.53 [0.27, 8.75]

3 Respiratory distress syndrome Show forest plot

12

3622

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.05, 1.53]

3.1 Greater than 34 weeks' gestation

5

2992

Risk Ratio (M‐H, Fixed, 95% CI)

1.45 [1.10, 1.90]

3.2 Less than 34 weeks' gestation

5

490

Risk Ratio (M‐H, Fixed, 95% CI)

1.09 [0.84, 1.43]

3.3 Not specified (wider span)

2

140

Risk Ratio (M‐H, Fixed, 95% CI)

0.81 [0.27, 2.42]

4 Caesarean section Show forest plot

12

3620

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.11, 1.44]

4.1 Greater than 34 weeks' gestation

5

2992

Risk Ratio (M‐H, Fixed, 95% CI)

1.22 [1.05, 1.42]

4.2 Less than 34 weeks' gestation

5

488

Risk Ratio (M‐H, Fixed, 95% CI)

1.46 [1.08, 1.96]

4.3 Not specified (wider span)

2

140

Risk Ratio (M‐H, Fixed, 95% CI)

1.21 [0.45, 3.28]

5 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Fixed, 95% CI)

0.49 [0.33, 0.72]

5.1 Greater than 34 weeks' gestation

3

847

Risk Ratio (M‐H, Fixed, 95% CI)

0.26 [0.12, 0.57]

5.2 Less than 34 weeks' gestation

4

418

Risk Ratio (M‐H, Fixed, 95% CI)

0.77 [0.45, 1.30]

5.3 Not specified (wider span)

1

93

Risk Ratio (M‐H, Fixed, 95% CI)

0.39 [0.15, 1.01]

6 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

6.1 Greater than 34 weeks' gestation

3

2562

Risk Ratio (M‐H, Fixed, 95% CI)

0.37 [0.10, 1.40]

6.2 Less than 34 weeks' gestation

4

418

Risk Ratio (M‐H, Fixed, 95% CI)

2.23 [1.29, 3.84]

Figures and Tables -
Comparison 3. Any planned birth versus expectant management (subgroup analysis by gestational age for inclusion in trial)
Comparison 4. Any planned birth versus expectant management (subgroup analysis by antibiotic use)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection Show forest plot

12

3625

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.66, 1.30]

1.1 Prophylactic antibiotics used

2

1702

Risk Ratio (M‐H, Fixed, 95% CI)

0.74 [0.42, 1.31]

1.2 Prophylactic antibiotics not used

8

880

Risk Ratio (M‐H, Fixed, 95% CI)

1.42 [0.81, 2.51]

1.3 Some prophylactic antibiotics used

2

736

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.30, 1.46]

1.4 Not specified

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.80 [0.25, 2.55]

2 Neonatal infection confirmed with positive culture Show forest plot

7

2925

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.70, 2.21]

2.1 Prophylactic antibiotics used

1

120

Risk Ratio (M‐H, Fixed, 95% CI)

0.16 [0.01, 2.99]

2.2 Prophylactic antibiotics not used

3

234

Risk Ratio (M‐H, Fixed, 95% CI)

1.63 [0.62, 4.28]

2.3 Some prophylactic antibiotics used

3

2571

Risk Ratio (M‐H, Fixed, 95% CI)

1.35 [0.62, 2.93]

3 Respiratory distress syndrome Show forest plot

12

3622

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [1.06, 1.56]

3.1 Prophylactic antibiotics used

1

120

Risk Ratio (M‐H, Fixed, 95% CI)

1.11 [0.23, 5.26]

3.2 Prophylactic antibiotics not used

7

630

Risk Ratio (M‐H, Fixed, 95% CI)

1.11 [0.85, 1.45]

3.3 Some prophylactic antibiotics used

3

2565

Risk Ratio (M‐H, Fixed, 95% CI)

1.48 [1.10, 1.99]

3.4 Not specified

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.55, 2.94]

4 Caesarean section Show forest plot

12

3620

Risk Ratio (M‐H, Fixed, 95% CI)

1.30 [1.14, 1.49]

4.1 Prophylactic antibiotics used

1

120

Risk Ratio (M‐H, Fixed, 95% CI)

1.47 [0.34, 6.30]

4.2 Prophylactic antibiotics not used

7

628

Risk Ratio (M‐H, Fixed, 95% CI)

1.43 [1.08, 1.90]

4.3 Some prophylactic antibiotics used

3

2565

Risk Ratio (M‐H, Fixed, 95% CI)

1.31 [1.12, 1.53]

4.4 Not specified

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.51, 1.61]

5 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Random, 95% CI)

0.50 [0.26, 0.95]

5.1 Prophylactic antibiotics used

1

120

Risk Ratio (M‐H, Random, 95% CI)

0.11 [0.01, 0.84]

5.2 Prophylactic antibiotics not used

5

511

Risk Ratio (M‐H, Random, 95% CI)

0.69 [0.34, 1.41]

5.3 Some prophylactic antibiotics used

2

727

Risk Ratio (M‐H, Random, 95% CI)

0.35 [0.15, 0.86]

6 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

6.1 Prophylactic antibiotics used

0

0

Risk Ratio (M‐H, Fixed, 95% CI)

0.0 [0.0, 0.0]

6.2 Prophylactic antibiotics not used

4

418

Risk Ratio (M‐H, Fixed, 95% CI)

2.23 [1.29, 3.84]

6.3 Some prophylactic antibiotics used

3

2562

Risk Ratio (M‐H, Fixed, 95% CI)

0.37 [0.10, 1.40]

Figures and Tables -
Comparison 4. Any planned birth versus expectant management (subgroup analysis by antibiotic use)
Comparison 5. Any planned birth versus expectant management (subgroup analysis by timing of early delivery)

Outcome or subgroup title

No. of studies

No. of participants

Statistical method

Effect size

1 Neonatal infection Show forest plot

12

3628

Risk Ratio (M‐H, Fixed, 95% CI)

0.93 [0.66, 1.30]

1.1 Less than 24 hours from randomisation

4

391

Risk Ratio (M‐H, Fixed, 95% CI)

0.90 [0.41, 1.99]

1.2 Greater than 24 hours from randomisation

7

2930

Risk Ratio (M‐H, Fixed, 95% CI)

0.95 [0.64, 1.41]

1.3 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.80 [0.25, 2.55]

2 Neonatal infection confirmed with positive culture Show forest plot

7

2925

Risk Ratio (M‐H, Fixed, 95% CI)

1.24 [0.70, 2.21]

2.1 Less than 24 hours from randomisation

2

213

Risk Ratio (M‐H, Fixed, 95% CI)

0.67 [0.18, 2.53]

2.2 Greater than 24 hours from randomisation

5

2712

Risk Ratio (M‐H, Fixed, 95% CI)

1.44 [0.76, 2.75]

3 Respiratory distress syndrome Show forest plot

12

3622

Risk Ratio (M‐H, Fixed, 95% CI)

1.29 [1.06, 1.56]

3.1 Less than 24 hours from randomisation

4

391

Risk Ratio (M‐H, Fixed, 95% CI)

0.99 [0.65, 1.50]

3.2 Greater than 24 hours from randomisation

7

2924

Risk Ratio (M‐H, Fixed, 95% CI)

1.37 [1.10, 1.71]

3.3 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [0.55, 2.94]

4 Caesarean section Show forest plot

12

3620

Risk Ratio (M‐H, Fixed, 95% CI)

1.26 [1.11, 1.44]

4.1 Less than 24 hours from randomisation

4

389

Risk Ratio (M‐H, Fixed, 95% CI)

1.59 [0.90, 2.81]

4.2 Greater than 24 hours from randomisation

7

2924

Risk Ratio (M‐H, Fixed, 95% CI)

1.27 [1.10, 1.46]

4.3 Not known

1

307

Risk Ratio (M‐H, Fixed, 95% CI)

0.91 [0.51, 1.61]

5 Chorioamnionitis Show forest plot

8

1358

Risk Ratio (M‐H, Random, 95% CI)

0.50 [0.26, 0.95]

5.1 Less than 24 hours from randomisation

3

342

Risk Ratio (M‐H, Random, 95% CI)

0.25 [0.10, 0.61]

5.2 Greater than 24 hours from randomisation

5

1016

Risk Ratio (M‐H, Random, 95% CI)

0.76 [0.41, 1.42]

6 Endometritis Show forest plot

7

2980

Risk Ratio (M‐H, Fixed, 95% CI)

1.61 [1.00, 2.59]

6.1 Less than 24 hours from randomisation

1

129

Risk Ratio (M‐H, Fixed, 95% CI)

1.67 [0.29, 9.68]

6.2 Greater than 24 hours from randomisation

6

2851

Risk Ratio (M‐H, Fixed, 95% CI)

1.60 [0.98, 2.63]

Figures and Tables -
Comparison 5. Any planned birth versus expectant management (subgroup analysis by timing of early delivery)